Protein-free calf blood dialysate - Educational materials

Actovegin: Therapeutic Power in Modern Medicine

Actovegin, a unique calf blood extract, is distinguished by its ability to increase the efficiency of our cells' oxygen utilization and better assimilation of nutrients. This process naturally increases blood flow to our brain. Why is this important? Because increased blood flow means our brain receives more energy, which can improve our memory.

Actovegin is produced from calf's blood by a special filtration process that captures small, beneficial chemical compounds. It contains ingredients smaller than 5,000 Da. People use actovegin for a variety of brain-related problems, such as memory deficiencies, injuries and even complications from diabetes.

But how exactly does actovegin work? At its core, it works by stimulating our cells to use and produce energy more efficiently. It also helps our brains assimilate glucose, a key source of energy, more efficiently. This unique ability has sparked discussion about its potential impact on overall performance.

The standout ingredient in actovegin is inositol-phosphoryl-oligosaccharides (IFOs). These ingredients play a key role in transporting glucose to our brains. In addition, they can penetrate the protective barrier around our brains and stimulate important enzymes responsible for glucose processing.

In this article we will discuss actovegin in detail, trying to reveal its benefits, uses and scientific basis that make it so effective.

Health benefits of actovegin supported by medical studies

Scientific studies have investigated the potential of actovegin in managing and preventing various medical cases. The following health effects are reported in various clinical trials and scientific studies.

Actovegin for Diabetes Patients

Actovegin appears to have many benefits for diabetes patients, from improving insulin response to helping them recover from serious illnesses and even potentially preventing nerve damage.

Actovegin offers a ray of hope for patients with diabetes, and recent studies have examined its potential benefits. One significant study involving 567 patients with diabetes examined the effects of actovegin on nerve pain. For 160 days, patients received treatment in the form of drips, followed by tablets. The results were promising: those treated with actovegin reported a reduction in nerve pain, increased foot sensitivity and an overall improvement in well-being, all without significant side effects [1]. Further studies have solidified actovegin's reputation as a potential breakthrough in the treatment of nerve pain in diabetics. For six months, patients with diabetes were given either actovegin or a placebo. The results showed a clear advantage for those taking actovegin, with marked improvements in pain relief. However, it was noted that patients taking certain blood pressure medications may not experience as much benefit [2].

In addition to relief from nerve pain, actovegin has shown potential in another key aspect of diabetes - blood sugar control. In a separate study with 40 participants (half of whom were diabetic), actovegin was administered for 14 days. Amazingly, the diabetic patients showed improved blood sugar control without any change in insulin levels [3].

In addition, one study examined the role of actovegin in wound care in diabetics. A cream containing human epidermal growth factor, combined with actovegin, was tested on diabetic foot ulcers in a group of 61 patients. Those who used the cream with the higher concentration of growth factor experienced as much as a 95% healing rate in just 12 weeks, highlighting actovegin's potential to accelerate healing of foot ulcers in diabetics [4].

Improving insulin sensitivity in type II diabetes: actovegin, made from calf's blood, was studied for its effect on improving our body's response to insulin in people with type II diabetes. When given as daily drips (actovegin 2000 pro infusions, 500 ml per day) for 10 days, the treatment increased the body's use of sugar by as much as 80% without changing insulin levels. Although we don't fully understand how this works, there is speculation that actovegin may provide special compounds (called IPOs) that can help cells better assimilate sugar [5].

Accelerating recovery from ketoacidosis in type 1 diabetes: Ketoacidosis is a serious condition in which the body's blood becomes too acidic. When actovegin was used together with another drug called reamberin, it helped patients return to consciousness and thinking faster. In fact, with this combination, people regained consciousness in only about 19.2 hours. What's more, they had better thinking skills that lasted up to 28 days after their crisis [6].

Diabetic neuropathy help: About one-third of diabetics suffer from nerve damage called neuropathy. In a study on rats with diabetic symptoms, actovegin improved nerve function and even reduced damage. It especially helped when given in higher doses, and perhaps works by calming harmful reactions in nerve cells [7].

Treating leg problems and diabetic foot ailments: In a study involving 200 patients with leg blood flow problems and diabetic foot disease, actovegin showed promising results. Some patients received actovegin before surgery, such as angioplasty, while others had it as their main treatment. In both cases, it worked well and was cost-effective. Depending on the severity of the condition, patients received different doses, either as injections or as tablets [8].

Based on these results, actovegin presents a promising pathway for the treatment and management of diabetes and its related complications. Its multifaceted benefits include increasing insulin sensitivity in type II diabetics, aiding recovery from diabetic crises and reducing nerve damage. These findings underscore actovegin's potential as a versatile therapeutic agent in the spectrum of diabetes care.

Actovegin in ulcer care

Actovegin pokazuje potencjalną rolę w zarządzaniu wrzodami, szczególnie dla osób z komplikującymi czynnikami, takimi jak choroba niedokrwienna serca czy cukrzyca.  Badanie z udziałem 194 pacjentów wykazało, że Ci, którzy byli leczeni actoveginem doświadczyli szybszego gojenia wrzodów i cieszyli się także dłuższymi okresami bez nawrotów [9]. Sugeruje to, że actovegin mógłby być korzystną opcją leczenia zarówno w warunkach szpitalnych, jak i ambulatoryjnych.

Effects of actovegin on gastroduodenal ulcers: In a separate study of refractory gastroduodenal ulcers (located in the stomach and initial part of the small intestine), the combination of actovegin with a technique called intralesional laser blood irradiation (ILBI) showed particularly promising results. Patients undergoing this combined treatment experienced noticeable pain relief, reduced inflammation and improved gastric mucosal health.

In addition, beneficial changes in gastric mucus composition have been noted, suggesting increased healing and metabolic activity of the gastric and intestinal mucosa. It appears that this combination not only aids in the physical healing process, but may also bring balance to certain regulatory substances in the body, providing effective treatment for refractory ulcers [10].

Benefits of actovegin for brain and nervous system health:

Actovegin is a substance derived from calf blood, and shows significant potential for supporting and improving brain and nervous system health, especially in cases of chronic brain anemia and age-related memory impairment.

Enhancing Thinking Ability After Stroke: After a stroke, returning to normal mental functioning can be a challenge. A study on elderly people who recently experienced a stroke found that actovegin could be a solution. Participants in the study were treated with actovegin, initially through an intravenous (IV) drip and then in pill form, for six months. The results revealed that those taking actovegin noticeably improved their performance on cognitive tests compared to the placebo group [11].

Promising Results for Brain Health in the Elderly: Older people, especially those with brain problems affecting memory and attention, may benefit from actovegin. In a study of 60 such individuals, those who took actovegin experienced significant improvements in mental performance. Significantly, 70% of those treated with actovegin felt significantly better, compared to only 35% in the placebo group [12].

Improving Memory and Reducing Thinking Problems: Aging sometimes brings early signs of memory and thinking problems. In one study, actovegin was given as daily injections to elderly people showing early signs of such problems. Results showed faster thinking, fewer memory problems and fewer feelings of sadness or fatigue [13].

Improving Overall Well-Being in the Elderly: For seniors, especially those with heart or brain-related health problems, actovegin pills may offer potential health benefits. When given to 70 elderly patients for six weeks, many reported improvements in memory, energy levels, sleep quality and overall strength [14].

Protecting Neurons and Reducing Cell Damage: At the cellular level, actovegin also demonstrated its power. In a study on rat neurons (cells crucial to brain function), exposure to actovegin increased cell numbers and connections. What's more, it showed properties that reduced potential cell damage and acted against harmful oxidative agents [15].

Supporting the Brain's Antioxidant System: In an experiment on rats with chronic brain anemia, administration of actovegin (5 ml/kg) played a key role in restoring the brain's antioxidant system. This included normalizing glutathione levels, restoring the activity of a protective enzyme called superoxide dismutase (SOD) and reducing harmful malondialdehyde (MDA) concentrations [16].

Improving Cognitive Function and Blood Flow: In a human study focusing on people with chronic cerebrovascular pathologies, as many as 81% patients treated with actovegin showed improvements in overall health and symptoms. Actovegin showed benefits in improving cognitive function, and results varied by dose [17].

Supporting Brain Activity and Cognitive Function: For the elderly, actovegin has been shown to be particularly beneficial for brain activity and cognitive function. In a placebo-controlled study involving middle-aged 65-year-olds, actovegin increased alpha and beta brain activity, indicating improvements in brain function and attention [18].

Improving Memory Disorders: Older adults with memory problems may find comfort in the potential benefits of actovegin. Studies indicate that actovegin makes positive changes in brain activity, especially in regions related to memory and attention [19].

Support in Aging Associated with Memory Impairment: In another study targeting patients with aging associated with memory impairment, actovegin improved and supported cognitive performance. Patients taking actovegin experienced a noticeable increase in brain activity, especially in the parietal cortex, which is important because reduced activity in this region is often seen in patients with dementia [20].

Based on these findings, actovegin appears to have a number of beneficial effects on brain and nervous system health, offering hope for people with ischemic diseases, memory disorders and other cerebrovascular problems.

Brain Injury Treatment Aid: A study of 68 brain injury patients showed that those who received actovegin (32 out of 68) experienced accelerated recovery. actovegin, administered as an IV of 400 mg per 200 ml mixed with a stock solution for 10 days, accelerated the recovery of lost brain function, reducing overall healing time. In addition, these patients experienced significant relief of fatigue symptoms and showed improvement in EEG studies, suggesting improved brain activity [21].

Improvement in Chronic Brain Anemia: Chronic cerebral anemia can cause energy deficiencies in the brain, especially in stages I-II, often associated with hypertension or cerebral atherosclerosis. A study comparing actovegin and Mexidol found that patients treated with both drugs had fewer clinical symptoms associated with the disease, improved cognitive brain function and a significant reduction in subjective symptoms of the disease. It is worth noting, however, that Mexidol had a unique advantage in addressing metabolic energy deficits [22].

Mitigating Cognitive Impairment in COVID-19: actovegin appears promising for treating the endothelial dysfunction seen in patients with COVID-19, which can lead to multiorgan failure and increase the risk of cognitive impairment. Actovegin not only enhances endothelial function and microcirculation, but also shows potential benefits in improving cognitive function, making it a potentially effective therapeutic option for patients with neurological or cognitive impairment caused by COVID-19 [23].

Increasing Cognitive Resources in Association with Age-Related Memory Impairment: A study evaluating the effects of actovegin on event-related potentials associated with cognitive function in patients with age-related memory impairment showed significant results. Patients receiving actovegin showed an increase in P300 amplitude, suggesting increased cognitive processing resources. This increase of up to 4.8 microV, especially in the central and parietal brain regions, was significant and indicates that actovegin may benefit certain aspects of cognitive function in those suffering from age-related memory problems [24].

Role in Ischemic Stroke Treatment: Ischemic stroke can drastically affect neurological and cognitive function. In a study comparing the effects of actovegin and piracetam on patients with mild to moderate ischemic stroke, actovegin showed a clear advantage. Patients treated with actovegin experienced significant improvements in overall brain symptoms and specific neurological signs. At the end of the treatment period, recovery rates, both in terms of total ischemic scores and cognitive function, were significantly higher in the actovegin-treated group, making it a powerful choice for treating ischemic stroke in its acute phase [25].

Protection from Hypoxia: A study involving 12 healthy young men examined how actovegin affects the brain during hypoxia, a condition characterized by low oxygen levels. The drug is designed to increase the transport of glucose and oxygen into cells. When participants were exposed to hypoxic conditions, measurements showed that certain signals in the brain, known as VEP-P2 and ERG-b-wave, tended to decrease. However, with actovegin treatment, these decreases were corrected, suggesting that the drug may protect central neuronal and perhaps even glial structures from the effects of hypoxia. Moreover, the infusion method, which introduces a higher dose of actovegin, has been shown to be more effective against the effects of hypoxia [26].

Enhancement of Learning and Memory Processes After Ischemia: In an experiment on rats that experienced cerebral ischemia, actovegin showed neuroprotective effects. The drug was administered to these rats, and their learning and memory abilities were assessed using the Morris water maze test. The results were promising: rats treated with actovegin showed faster learning and better memory retention. In addition, microscopic examination of their brains showed that there was greater cell survival in a key region associated with memory, called the hippocampal CA1 region [27].

Improved Lipid Profile in Hypertensive Patients: In patients with chronic cerebral anemia and hypertension, actovegin, in combination with ceretone, effectively corrected abnormalities in the lipid profile, which is crucial for erythrocyte membrane stability and structure. This combination therapy significantly outperformed other drug combinations [28].

Increased Cerebral Blood Flow in Metabolic Syndrome: A study on patients suffering from metabolic syndrome showed that combining actovegin with the drug bisoprolol significantly increases cerebral blood flow, even more than with bisoprolol alone. Increased blood flow to the brain is crucial to its proper functioning and health [29].

Promising Treatment for Cerebral Circulation Failure: In patients showing early signs of cerebral circulation problems, actovegin, in combination with Corinfar, showed significant improvement. The combination therapy appeared to normalize most parameters related to microcirculation and blood rheology, suggesting its potential as a treatment option for patients with cerebral circulation problems [30].

These studies support actovegin's potential to protect brain health and improve cerebral circulation.

Treatment of dyssyrrculatory encephalopathy in hypertension: In a study involving 56 patients with a diagnosis of dyssyrrculatory encephalopathy due to hypertension, treatment with both actovegin and Captopril produced positive clinical results. The results strongly suggest a potential benefit of using actovegin in combination with Captopril to treat such conditions [31].

Improving microcirculation in the limbs: Distal lower limb occlusion is a serious medical problem. In a study involving 60 patients with critical limb ischemia, those treated with actovegin experienced a significant 35 percent improvement in skin perfusion by day 15. Moreover, there was a 12.8 percent increase in microcirculation, which increased tissue oxygenation. This shows that actovegin may play a key role in improving blood flow in patients with distal limb occlusion [32].

Comparison with solcoseril: In a study to compare the effects of actovegin and solcoseril on microcirculation in the lower extremities of anemic patients, it was found that both treatments had a positive effect on the formation of new capillaries. However, actovegin stood out in particular, showing better results in improving microcirculatory dynamics and promoting a denser capillary network [33].

Support for recovery after stroke: In a study involving 104 patients with acute ischemic carotid artery stroke, those who received 250 ml of actovegin daily showed significant improvements in neurological progress and functional recovery by day 30, compared to the control group. The level of statistical significance was recorded as p < 0.005. This indicates that actovegin has the potential to significantly enhance post-stroke recovery without causing negative side effects [34].

Reduced risk of stroke in patients with chronic cerebral anemia: Patients with chronic cerebral anemia are at risk of experiencing a stroke within 10 years. A study involving 54 patients highlighted that those with vertebrobasilar anemia are at particular risk. However, actovegin showed impressive therapeutic effects on autonomic nervous systems. The study further revealed actovegin's ability to affect blood vessel walls through various pathways, which in turn showed promising hypotensive effects. This suggests that actovegin may reduce the long-term risk of stroke in such patients [35].

Based on these results, actovegin presents itself as a versatile drug with potential benefits in treating a variety of medical conditions, from improving microcirculation in the extremities, to supporting recovery from stroke, to reducing long-term stroke risk.

Neuroprotective properties after ischemic stroke: A study in rats showed that after experiencing an ischemic stroke, a dose of decongested calf serum (actovegin/Solcoseryl) significantly reduced neurological damage and volume of the affected brain within 24 hours. This is particularly striking compared to rats that did not receive this treatment (with statistical significance of p < 0.0005). The serum works by counteracting the negative effects of hypoxia-glucose on nerve cells, reducing harmful forms of reactive oxygen species and preventing cell death. The result is less cell damage and better survival rates for these cells [36].

Improving treatment for carotid artery ischemia: A study involving 25 patients with moderate carotid artery ischemic stroke demonstrated the potential benefits of actovegin. In combination with other neuroprotective agents, the treatment led to noticeable improvements in patient recovery. In just 21 days, patients on this combined treatment experienced a reduction in neurological deficits, better overall functional recovery, and reduced inflammatory indices compared to those on standard care [37].

Enhancing antidepressant treatment for the elderly: In elderly patients diagnosed with mild to moderate depression, actovegin has been studied as a potential addition to a new generation of antidepressants. The study showed that adding actovegin to standard antidepressant treatment resulted in faster and more pronounced therapeutic effects. By week 4, patients on the combined therapy showed significant reductions in depressive symptoms, improvements in cognitive function and a higher rate of positive responses. This suggests that actovegin may help speed up recovery and potentially even shorten hospital stays for elderly patients [38].

Best combination for chronic cerebral ischemia: When evaluating different drug combinations for the treatment of chronic cerebral ischemia, the combination of actovegin and Cereton proved to be the most effective, suggesting that this combination may offer optimal therapeutic outcomes [39].

Post-stroke rehabilitation: actovegin was highlighted in a large study involving 1,920 post-stroke patients. The study showed that among several drugs tailored for ischemic stroke patients, actovegin stood out as one of the most effective. Moreover, for patients recovering from hemorrhagic stroke, actovegin was the only drug that had a positive effect on rehabilitation [40].

Based on these results, actovegin appears to offer multiple benefits in a variety of medical scenarios, from improving recovery after stroke to enhancing the effectiveness of antidepressants in the elderly. The aforementioned studies provide significant evidence of its therapeutic potential, making it an exciting area for further research.

Recovery from post-operative stroke: After surgery for acute abdominal conditions, some patients may develop acute cerebrovascular disorders. These disorders can range from transient ischemic attacks, acute hypertensive encephalopathy, to various types of strokes. Interestingly, as many as 86.9% of these disorders occur within the first three days after surgery. Actovegin, especially when administered within the first 24 hours after surgery, shows the potential to accelerate recovery from these neurological deficits. This treatment not only promotes faster recovery, but also helps improve cerebral blood flow in patients who have suffered post-operative strokes [41].

Neuroprotective role in cerebral ischemia: Cerebral ischemia refers to a lack of blood supply to the brain, which can lead to brain damage or stroke. In experiments on rodent models that mimicked conditions of both sudden and gradual reduction in blood supply to the brain, actovegin proved beneficial. In particular, it aided in the recovery of neurological function and reduced the negative effects of sensory, motor and cognitive impairment in rats [42].

Inhibitory effect on harmful oxygen radicals: Oxidative stress, which includes the production of harmful oxygen radicals, plays a role in many chronic diseases. Patients with heart failure may experience an increase in these harmful radicals. Actovegin reduces the formation of these radicals. In some cases, even a low dose of less than 1 mg/mL was sufficient to see this inhibitory effect. Furthermore, when human neuroblastoma cells (a model for nerve cells) were exposed to hydrogen peroxide, a substance that can lead to cell death, pretreatment with actovegin noticeably reduced this cell death. It is thought that actovegin may act not only by reducing certain harmful substances, but also by neutralizing the effects of other highly reactive molecules in the cells. These findings underscore the potential role of actovegin in reducing the chronic inflammation often associated with heart failure and its protective effects on the central nervous system [43].

In conclusion, actovegin presents itself as an exciting avenue for medical treatment. From promoting recovery from post-surgical strokes, to playing a neuroprotective role, to counteracting harmful radicals, its therapeutic benefits, as demonstrated by various studies, make it a noteworthy agent in medical science.

Korzyści z actoveginu dla zdrowia fizycznego, ruchomości i regeneracji  mięśni

Actovegin has shown promising results in improving physical mobility, especially in patients suffering from peripheral artery disease (PAD) and those undergoing physiotherapy.

Improvement in patients with PAD: A study involving participants from Russia, Georgia and Kazakhstan aimed to evaluate the efficacy of actovegin in the treatment of PAD [44]. Participants underwent an initial two-week intravenous treatment with actovegin, followed by a 10-week oral treatment. By week 12, there was a nearly 29% improvement in the distance participants could walk without experiencing pain. This progress was more than 35% at the end of the 24th week, which meant that participants could walk an additional 41 meters without discomfort. In addition, their overall walking ability increased by 36%. Moreover, those treated with actovegin reported a better quality of life according to the SF-36 Mental Health Scale. This study also confirmed that actovegin has minimal side effects, confirming its safety [44].

Improved physiotherapy outcomes: Adding actovegin to standard physiotherapy procedures resulted in improved mobility outcomes. In a study involving 105 patients, intravenous administration of actovegin along with baseline physiotherapy led to 12% improvement in walking ability compared to the placebo group [45]. This means that actovegin can enhance the benefits of regular physiotherapy, offering patients improved mobility and physical independence.

Increased walking ability in patients undergoing physiotherapy: In another study, researchers focused on 105 participants undergoing physiotherapy. Those who were treated with intravenous actovegin increased their walking ability by 12% more than those who received placebo, reinforcing the notion that actovegin can increase the effectiveness of physiotherapy [46]. Importantly, both groups responded well to baseline physiotherapy, indicating that actovegin is a potential enhancer, not the only treatment.

Thus, these studies indicate that actovegin has potential as an additional treatment in improving physical health, mobility and muscle recovery. For those with PAD or undergoing physiotherapy, it offers hope for increased mobility and a better quality of life.

Benefits of actovegin for Muscle Regeneration and Strengthening (in sports/athletes)

Actovegin has shown impressive results in promoting muscle recovery and stimulating cell growth. In a study with 103 participants, those with muscle injuries received injections of actovegin directly into the injured area, at intervals of several days. The results were impressive. Recovery time for those treated with actovegin was about 5.5 weeks, almost three weeks shorter than for those who received a placebo. This means that athletes or anyone suffering from a muscle injury can get back in shape almost three weeks sooner than with traditional treatments, which could be a breakthrough for those involved in competitive sports [47].

In addition to helping with regeneration, actovegin also appears to play a key role at the cellular level. When muscle cells, specifically C2C12 myoblasts, were treated with actovegin, a significant improvement in their growth was observed. Important markers of cell growth, such as Ki67 and myosin heavy chains, increased significantly in the presence of actovegin, indicating increased proliferation of muscle cells. This study suggests that actovegin may contain components beneficial to muscle cells and may help them grow more efficiently [48].

Investigating actovegin's potential to enhance physical performance, another study examined its effects on human skeletal muscles. The results revealed that actovegin improved the ability of mitochondria in muscle cells to respire. It increased the ability of muscles to use oxygen for energy production. These results support actovegin's potential as a possible performance enhancer for individuals (athletes) seeking to enhance their physical abilities. Although further research is required, these results may have implications for its use in sports [49].

Moreover, in a competitive sports environment, another study highlights the advantages of combined treatment. Actovegin combined with the homeopathic drug Tr14 can significantly accelerate muscle recovery. The combined treatment appeared to promote the expression of genes and proteins that promote muscle growth, leading to faster recovery from injuries. For athletes, this could mean a faster return to the field after suffering a muscle injury [50].

Based on these results, actovegin, alone or in combination with other treatments, shows promising potential in accelerating muscle recovery, promoting cell growth and the potential to even enhance athletic performance. Its benefits are evident in various studies, making it a valuable component in sports medicine and rehabilitation.

Effects of actovegin on Oxygen Metabolism and Utilization

Actovegin, known mainly for its metabolic and neuroprotective properties, has shown a significant impact on the way our bodies use oxygen.

The study showed that actovegin indirectly improves the efficiency of oxygen utilization in tissues. Specifically, it increases the amount of oxygen that red blood cells (erythrocytes) can carry [51]. This unique property allows actovegin to act as an anti-hypoxia agent, which is particularly helpful for patients experiencing acute gastric distress [51]. In another study, actovegin significantly improved the entire process of oxygen management in the body, further highlighting its ability to counteract hypoxia [52].

In pregnant women experiencing complications such as impaired umbilical cord blood flow or placental circulation leading to fetal hypoxia (insufficient oxygen supply to the fetus), actovegin combined with 5% glucose and vitamin C showed promising results. The IV solution effectively treated fetal hypoxia in a significant number of test cases, preventing possible complications at birth. The role of actovegin here was mainly to modify metabolic processes and protect key areas from the negative effects of oxygen deficiency [53].

Moreover, in an experiment with healthy volunteers, actovegin demonstrated an effect on the relationship between metabolic activities and microcirculatory processes in the skin. Significant changes were observed in several parameters, such as 98% increase in endothelial rhythm amplitude, indicating a link between metabolic processes and microhemodynamics in the skin [54].

In stressful situations, as in a study in which rats experienced prolonged immobilization stress, the soft and hard tissues of the periodontium (parts of the gums and teeth) showed a decrease in oxygen levels and metabolism. However, the introduction of actovegin (along with Thiotriazolin) helped to offset these stress effects by maintaining the oxygen balance in these tissues [55].

All of these results point to the promising potential of actovegin in a variety of medical scenarios, particularly with regard to oxygen utilization and metabolism. Whether it's athletes in need of faster recovery, high-risk pregnancies or those experiencing acute health problems, actovegin's ability to improve oxygen utilization may be the solution many are looking for.

Benefits of actovegin for eye health

Actovegin has shown promising potential in improving the health of our eyes, especially in conditions related to vision problems caused by various causes.

In a study targeting elderly people with retinal problems caused by high blood pressure, the addition of actovegin to standard treatment for hypertension produced encouraging results. Specifically, 36% elderly participants saw not only improvements in vision, but also increased mood and quality of life [56].

In another innovative approach, the researchers investigated a new method of delivering drugs directly into the vascular system of the eye. Using this method, they administered actovegin and trental to a group of patients suffering from vision problems associated with nerve damage in the eye. The results were quite impressive - the patients' visual acuity increased significantly, from low scores of 0.03-0.06 to much sharper scores of 0.3-0.8. In addition, some of the eye problems, such as central scotomas, disappeared, and the conduction of the axial optic nerve bundle improved significantly [57].

Further evidence suggests that actovegin may also play a role in the treatment of a specific ocular condition known as optic nerve neuropathy in the course of glaucoma, particularly in patients with open-angle glaucoma (POAG) occurring together with myopia. The group of participants, all with a diagnosis of POAG and high myopia, were treated with a protocol that included actovegin among other drugs. The treatment was designed to address a variety of issues, from blood flow dynamics to metabolic shifts, affecting the progression of glaucoma in people with myopia [58].

These results indicate that actovegin's benefits for eye health are diverse and continue to be explored in a variety of contexts, from improving visual acuity in the elderly, to innovative drug delivery for increased visual acuity, to treating specific eye conditions.

Benefits of actovegin for skin health

Actovegin has shown promising benefits for skin health as well.

In one study, researchers examined how actovegin affects blood flow and metabolism in the skin. Twenty-eight volunteers were given actovegin intravenously, and then blood flow in the skin of the forearm was measured using advanced instruments, and fine blood vessels in the nail were observed. The results showed that actovegin not only improved blood flow in the skin, but also increased the overall metabolic activity of skin cells. This means that skin cells were more active and healthier after actovegin administration. In addition, it was noted that it led to better vasomotion (movement of blood vessels) in different rhythms, which can be interpreted as better skin health at the micro level [59].

Another interesting aspect of actovegin's potential benefits for skin health is its radioprotective properties. Actovegin appears to provide a protective shield for skin cells when they are exposed to harmful radiation. In a particular experiment, human skin cells were exposed to a dose of X-rays, resulting in a significant decrease in cell numbers. However, when these cells were treated with actovegin, not only did a higher percentage survive the radiation, but their numbers even increased slightly. Even more impressively, using actovegin alone without radiation led to a fivefold increase in cell numbers in just six days! At the molecular level, actovegin was able to reduce the expression of a protein (EGFR) that normally increases when skin cells are exposed to radiation. This suggests that actovegin may counteract some of the damaging effects of radiation on our skin, which is an important finding given the various sources of radiation we are exposed to in today's world [60].

These results indicate that actovegin presents great promise for skin health, from improving blood flow and metabolism in skin cells to protecting against radiation damage.

Benefits of actovegin for digestive health

Actovegin is also presented in scientific studies as a means to protect and heal the digestive system, especially from radiation injury.

The study, conducted on Wistar rats, was designed to examine the effects of radiation on small intestinal mucosal epithelial cells and see how actovegin might help. The researchers irradiated the abdomens of these rats and then treated some of them with different doses of actovegin. In the group exposed to radiation alone, there was a significant increase in levels of IL-2 and IL-6 - indicators of inflammation. However, the rats that received actovegin after radiation showed significantly better health in their intestinal tissues. Specifically, the structure and thickness of their intestinal layers improved [61].

At the molecular level, actovegin has played a role in reducing harmful proteins that cause cell death (apoptosis) and increasing beneficial proteins that prevent apoptosis. In essence, actovegin has demonstrated its ability to defend intestinal cells from the negative effects of radiation, indicating its potential for treating conditions such as radiation enteritis, an inflammation of the intestines caused by radiation [61].

In another study, researchers reported that actovegin can help recovery from radiation-induced intestinal damage. After exposure to radiation, some rats received injections of actovegin. The results were consistent with the previous study: those treated with actovegin showed significant improvements in intestinal health. The height of their intestinal villi, the depth of their crypts (small valleys in the intestines) and the overall thickness of the mucosal lining were all better. Again, at the cellular level, actovegin was key in balancing proteins that control cell death, promoting intestinal cell survival and health. This study indicates the potential of actovegin to treat radiation-induced intestinal damage [62].

Other health benefits of actovegin

Actovegin has shown many promising benefits in various health studies. Here are some key findings from scientific studies:

Enhancing neutrophil function after freezing: actovegin can renew neutrophils, a type of white blood cell crucial to the immune response. In a study comparing actovegin with bovine cord blood fraction, both agents increased the ability of neutrophils to engulf and digest harmful entities after freezing and thawing. Specifically, upon exposure to 1.5 mg/mL actovegin, neutrophils showed improvements in oxygen-related metabolism, which is crucial for their function [63].

Promoting sperm production after clinical death in rats: Male rats that experienced simulated clinical death had a significant decrease in the production of sperm and related cells. However, after a dose of actovegin, the negative effects were negated. Moreover, sperm production returned to normal within 45 days after resuscitation [64].

Benefits for patients with metabolic syndrome: A study involving patients with metabolic syndrome, a condition associated with an increased risk of heart disease, stroke and diabetes, used a combination therapy of actovegin and pancreatic enzymes. The combination significantly improved small intestinal function, leading to better digestion, absorption and movement of food through the intestines. In addition, patients showed lower levels of triglycerides, total cholesterol and other harmful factors [65].

Alleviating symptoms of post-thrombotic disease in the lower extremities: actovegin has been studied for its benefits for patients with post-thrombotic disease, a condition following deep vein thrombosis. Included in the treatment plan, patients reported numerous improvements. This includes significant reductions in ankle swelling, tingling sensation, cramping frequency, pain intensity and overall improvement in quality of life [66].

Improving outcomes for patients undergoing carotid artery surgery: Carotid endarterectomy is a surgical procedure designed to prevent strokes in patients with significant blockages in the carotid arteries. A group of patients, prior to undergoing this surgery, received actovegin. This "preconditioning" led to improved cerebral blood flow and better surgical outcomes. Moreover, significant cognitive improvements were noted in these patients, both one week and six months after surgery [67].

Preventing clefts in expectant mothers with a history of clefts: Between 1980 and 2005, a group of 71 women with a personal or family history of clefts received a prophylactic regimen that included both vitamin B complex and actovegin, administered twice a week. As a result, a significant number, 80 out of the total number of births, resulted in healthy children. The risk of having children with clefts was reduced to 2.9% for cleft lip and palate (CLP) and was 0% for cleft palate (CP), compared to previously known risks of 4.9% for CLP and 2.4% for CP [68].

Improved results of carotid artery surgery: A study of 80 patients with carotid artery problems found that those who received a daily dose of 1,200 mg of actovegin for 1.5 months before surgery had better postoperative outcomes. Specifically, they had improved cerebral blood flow, which was observed both 7 days and 6 months after surgery. This treatment also reduced the chances of asymptomatic ischemic strokes after surgery [69].

Treatment of radiotherapy-induced oral ulcers: actovegin proved effective in treating radiotherapy-induced oral ulcers in cancer patients. Patients treated with actovegin experienced significantly less pain and had milder oral ulcers after two weeks. In addition, inflammatory markers in the blood were significantly lower than those treated with other agents [70].

Beneficial for cancer patients undergoing combined treatments: actovegin has been studied in the context of its effects on cancer patients undergoing combined chemotherapy and radiation therapy. One significant side effect of such treatment is painful oral ulcers. Patients who received actovegin from the beginning of their treatment were significantly less likely to develop severe ulcers. Moreover, for those who started actovegin after ulcers appeared, there were fewer progressing to severe ulcers [71].

Successful treatment of chronic limb disease: In a study focused on the treatment of chronic limb artery occlusive disease (CODLLA), 80 patients were observed. Half of them were treated with actovegin. After treatment, this group experienced a 56% increase in certain blood flow parameters, indicating improved circulation. In addition, the distance they could walk without pain increased by almost 59% [72].

The results indicate that actovegin has demonstrated a wide range of beneficial effects in a variety of medical contexts, from preventing clefts in expectant mothers, to improving outcomes in surgery, cancer treatments, and chronic limb diseases.

Mechanism of action of actovegin in various medical conditions

Based on available data, actovegin shows a complex and multifaceted mechanism of action beneficial to a wide range of medical conditions. In neurology, it shows strong neuroprotective properties. It helps nerve function, relieve pain and improve cognitive function, especially in conditions such as type 1 and type 2 diabetes and stroke. Laboratory experiments have shown that actovegin promotes neuronal survival and synaptic plasticity, and exhibits anti-apoptotic effects by reducing levels of activated caspase-3.

In addition, actovegin exhibits significant antioxidant properties. It reduces the production of reactive oxygen species (ROS) and revitalizes key antioxidant systems, effectively restoring metabolic balance. In particular, it normalizes levels of lactose, pyruvate and glutathione, and renews the activity of key antioxidant enzymes such as superoxide dismutase (SOD) and catalase. These properties are particularly useful in conditions characterized by oxidative stress and inflammation, such as heart failure.

The compound also plays a role in blood sugar regulation, improving glucose tolerance and insulin sensitivity in patients with type II diabetes. This action may be related to its known effects on improving glucose and oxygen utilization at the cellular level, crucial for conditions such as ischemia where tissue perfusion is limited.

Actovegin also has pronounced effects on wound healing, as it accelerates the healing of ulcers on the feet and duodenal ulcers. It increases the elasticity of erythrocytes and promotes microcirculation, thereby improving blood flow and stimulating the blood supply needed to heal ulcers and ischemic tissues. Moreover, actovegin has been shown to improve memory, concentration and attention, as demonstrated by increased alpha and beta activity in EEG studies. This is particularly useful for older patients showing signs of cognitive impairment.

In addition, actovegin has shown benefits in accelerating recovery from brain injury and stroke, likely due to its anti-inflammatory and antioxidant effects. In addition, the drug affects lipid profiles, improves both cerebral and peripheral circulation, affects autonomic homeostasis and enhances antidepressant treatment.

How to take actovegin: tablets and injections

actovegin is available in various formulations for different therapeutic requirements. Significantly, the two main forms are tablets and injections. The tablet form provides a convenient oral dosing option, ideal for extended treatment periods or maintenance phases.

The injectable form of actovegin, on the other hand, can be administered both intravenously and intramuscularly, offering rapid action and usefulness for more acute conditions or the initial phases of treatment. These different formulations ensure that actovegin can meet the specific needs of patients in a variety of therapeutic scenarios.

How to dose actovegin in different studies for different conditions

Actovegin, derived from calf blood, has been the subject of various studies, each examining its potential in different medical contexts. One notable study on type II diabetes mellitus (NIDDM) evaluated the drug's effectiveness in improving insulin sensitivity. In this particular study, ten patients with NIDDM received actovegin at a dose of 500 ml per day (actovegin 2,000 pro infusions) for ten days. Another study, focusing on people with chronic lower extremity ischemia and diabetic foot syndrome, evaluated the therapeutic use of actovegin both as an additional treatment for surgical interventions and as a stand-alone method. In severe cases, the drug was administered in doses of 1,000 to 2,000 mg intravenously over 10 to 15 sessions. Meanwhile, milder cases saw doses between 400-800 mg administered intramuscularly, followed by a switch to a tablet form for continued therapy.

A study targeting older people showing early signs of cognitive problems administered 5 ml (200 mg) injections of actovegin daily for 4 weeks. In a separate study that delved into the drug's effects on people with chronic cerebrovascular pathology and mild cognitive impairment, patients were divided into two groups based on their actovegin doses: either 1,000 mg or 160 mg daily. In the context of traumatic brain injury, another study showed a treatment protocol in which actovegin was administered as an IV, at exactly 400 mg per 200 ml mixed with a standard solution, and treatment continued for 10 days. Finally, in a study of acute carotid ischemic stroke, patients in one study arm were treated with 250 ml of actovegin daily. These varying doses underscore the diverse uses and therapeutic ranges of actovegin in various medical conditions.

Different dosages in different studies for different conditions

• Post-thrombotic disease of the lower extremities:

Dosage: intravenous 1200 mg dissolved in saline initially, followed by an oral dose of 1200 mg.

Duration: intravenously for 10 days, then orally daily for 30 days.

• Carotid endarterectomy in patients with chronic cerebrovascular insufficiency:

Dosage: 1,200 mg per day.

Duration: 1.5 months before surgery.

• Contingency before carotid endarterectomy:

Dosage: 1,200 mg of actovegin daily.

Duration: 1.5 months before surgery.

Side effects and precautions for actovegin

Actovegin, like all drugs, can cause side effects, but not everyone will experience them. Some side effects include:

Allergic reactions: This is one of the most severe side effects of actovegin. Symptoms can include skin rash, hives, reddening of the skin with a burning sensation and even symptoms of shock. Fever caused by the drug is also possible.

Dizziness: some users have reported feeling dizzy after taking actovegin.

Stomach discomfort: Especially after taking higher doses, some people reported stomach discomfort.

Caution when using actovegin:

• Allergies: Do not use actovegin if you are hypersensitive to skimmed calf blood serum or to any of the substances contained in the drug.
• Pregnancy and breastfeeding: Consult your doctor before taking actovegin if you are pregnant, think you may be pregnant, are planning a pregnancy or are breastfeeding.
• Interactions with other drugs: According to available data, no interactions of actovegin with other drugs have been found. However, always inform your doctor about all medications you are taking.
• Dietary restrictions: actovegin tablets should be taken before meals. They contain certain amounts of sodium, potassium and sucrose, which may be important for people on special diets or with certain medical conditions.
• Children: there is a lack of data on the use of actovegin in children. Therefore, its use in this group is not recommended unless prescribed by a doctor.
• Driving and operating machinery: actovegin may have minimal or no effect on the ability to drive and operate machinery. However, given that dizziness is a potential side effect, caution is advised.
• Patients with phenylketonuria: actovegin contains phenylalanine, which may be harmful to patients with phenylketonuria.
• Patients with certain dietary restrictions: Due to the sodium and potassium content, those on a sodium or potassium controlled diet should take this into consideration.
• Overdose: According to the data provided, no cases of actovegin overdose have been reported. Nevertheless, it is always recommended to adhere to the recommended dose and consult a doctor if an overdose is suspected.

Although actovegin has been shown to be beneficial for many conditions, it is important to take the drug as directed and be aware of potential side effects and precautions. Always consult your doctor before starting or stopping any medication.

Summary

Actovegin has demonstrated itself as a versatile therapeutic agent with benefits in numerous medical fields. It has shown significant effects in patients with diabetes, aiding in both metabolic and neurological aspects, particularly highlighting its neuroprotective attributes. In addition, its contributions to stroke recovery, sports medicine and the potential to enhance the effects of antidepressants in the elderly population underscore its broad applications. Moreover, its promising potential in eye health and its role in skin protection and restoration confirm its broad therapeutic potential. In short, actovegin's extensive and diverse therapeutic benefits point to its growing importance and potential role in modern medicine.

References

1. Ziegler, D., Movsesyan, L., Mankovsky, B., Gurieva, I., Abylaiuly, Z., & Strokov, I. (2009). Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes care, 32(8), 1479-1484. https://doi.org/10.2337/dc09-0545 https://pubmed.ncbi.nlm.nih.gov/19470838/
2. Ziegler, D., Edmundson, S., Gurieva, I., Mankovsky, B., Papanas, N., & Strokov, I. (2017). Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. Journal of diabetes and its complications, 31(7), 1181-1187. https://doi.org/10.1016/j.jdiacomp.2017.03.012 https://www.sciencedirect.com/science/article/pii/S1056872716305086
3. Heidrich, H., Quednau, J., & Schirop, T. (1979). Blutzucker- und Seruminsulinverhalten bei intravenöser Langzeittherapie mit actovegin [Reaction of blood sugar and serum insulin to intravenous longterm treatment with actovegin. Clinical double-blind study (author's transl)]. Medizinische Klinik, 74(7), 242-245. https://pubmed.ncbi.nlm.nih.gov/763217/
4. Tsang, M. W., Wong, W. K., Hung, C. S., Lai, K. M., Tang, W., Cheung, E. Y., Kam, G., Leung, L., Chan, C. W., Chu, C. M., & Lam, E. K. (2003). Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes care, 26(6), 1856-1861. https://doi.org/10.2337/diacare.26.6.1856 https://pubmed.ncbi.nlm.nih.gov/12766123/
5. Jacob, S., Dietze, G. J., Machicao, F., Kuntz, G., & Augustin, H. J. (1996). Improvement of glucose metabolism in patients with type II diabetes after treatment with a hemodialysate. Arzneimittel-Forschung, 46(3), 269-272. https://pubmed.ncbi.nlm.nih.gov/8901147/
6. Kligunenko, E. N., & Sedinkin, V. A. (2011). Eksperimental'naia i klinicheskaia farmakologiia, 74(12), 15-18. https://pubmed.ncbi.nlm.nih.gov/22379876/
7. Dieckmann, A., Kriebel, M., Andriambeloson, E., Ziegler, D., & Elmlinger, M. (2012). Treatment with actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association., 120(3), 132-138. https://doi.org/10.1055/s-0031-1291248 https://pubmed.ncbi.nlm.nih.gov/22020669/
8. Dibirov M. D. (2014). Khirurgia, (2), 33-36. https://pubmed.ncbi.nlm.nih.gov/24736538/
9. Smolianinov A. B. (2000). Lechenie aktoveginom bol'nykh iazvennoĭ bolezn'iu dvenadtsatiperstnoĭ kishki, sochetannoĭ s ishemicheskoĭ bolezn'iu serdtsa i sakharnym diabetom [Actovegin treatment of duodenal ulcer associated with ischemic heart disease and diabetes mellitus]. Klinicheskaia meditsina, 78(6), 24-28. https://pubmed.ncbi.nlm.nih.gov/10900865/
10. Vakhrushev, I.aM., & Shkatova, E. I.u (2003). Otsenka terapevticheskoĭ éffektivnosti sochetannogo primeneniia nizkointensivnogo lazernogo izlucheniia i aktovegina pri trudno rubtsuiushchikhsia iazvakh zheludka i dvenadtsatiperstnoĭ kishki [Therapeutic efficiency of a combined use of low-intensity laser radiation and actovegin in gastroduodenal ulcers with inhibited cicatrix formation]. Terapevticheskii arkhiv, 75(9), 86-89. https://pubmed.ncbi.nlm.nih.gov/14582442/
11. Guekht, A., Skoog, I., Edmundson, S., Zakharov, V., & Korczyn, A. D. (2017). ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind actovegin): A Randomized Controlled Trial to Assess the Efficacy of actovegin in Poststroke Cognitive Impairment. Stroke, 48(5), 1262-1270. https://doi.org/10.1161/STROKEAHA.116.014321 https://pubmed.ncbi.nlm.nih.gov/28432265/
12. Kanowski, S., Kinzler, E., Lehmann, E., Schweizer, A., & Kuntz, G. (1995). Confirmed clinical efficacy of actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry, 28(4), 125-133. https://doi.org/10.1055/s-2007-979604 https://pubmed.ncbi.nlm.nih.gov/7491366/
13. Mikhaĭlova, N. M., Selezneva, N. D., Kalyn, I.aB., Roshchina, I. F., & Gavrilova, S. I. (2013). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(7 Pt 2), 69-76. https://pubmed.ncbi.nlm.nih.gov/23994934/
14. Kopp H. (1979). Orale actovegin-Therapie bei zerebrovaskulärer Insuffizienz. Untersuchung über die therapeutische Wirksamkeit von actovegin forte Dragées bei Alterspatienten mit fortgeschrittenen zerebrovaskulären Insuffizienzerscheinungen [Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency]. Fortschritte der Medizin, 97(7), 307-312. https://pubmed.ncbi.nlm.nih.gov/437665/
15. Elmlinger, M. W., Kriebel, M., & Ziegler, D. (2011). Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular medicine, 13(4), 266-274. https://doi.org/10.1007/s12017-011-8157-7 https://pubmed.ncbi.nlm.nih.gov/21983748/
16. Kurkin, D. V., Morkovin, E. I., Kalatanova, A. V., Bakulin, D. A., Verholyak, D. V., Kovalev, N. S., Dubrovina, M. A., Tyurenkov, I. N., & Petrov, V. I. (2021). Antioksidantnoe deistvie Korteksina, Tserebrolizina i Aktovegina u zhivotnykh s khronicheskoi ishemiei golovnogo mozga [Antioxidant effect of cortexin, cerebrolysin and actovegin in rats with chronic cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 121(7), 84-89. https://doi.org/10.17116/jnevro202112107184 https://pubmed.ncbi.nlm.nih.gov/34460162/
17. Tanashyan, M. M., Shabalina, A. A., Lagoda, O. V., Raskurazhev, A. A., & Konovalov, R. N. (2018). Multimodal approach to treatment of neurological complications of chronic brain ischemia. Terapevticheskii arkhiv, 90(12), 61-67. https://doi.org/10.26442/00403660.2018.12.000010 https://pubmed.ncbi.nlm.nih.gov/30701835/
18. Saletu, B., Grünberger, J., Linzmayer, L., & Stöhr, H. (1984). Zur Funktionsverbesserung des alternden Gehirns: Placebokontrollierte Pharmako-EEG und psychometrische Studien mit einem stoffwechselaktiven Hämoderivat (actovegin) [Functional improvement of the aging brain: placebo controlled pharmaco-EEG and psychometric studies with a metabolically active hemoderivative (actovegin)]. Zeitschrift fur Gerontologie, 17(5), 271-279. https://pubmed.ncbi.nlm.nih.gov/6395527/
19. Saletu, B., Grünberger, J., Linzmayer, L., Anderer, P., & Semlitsch, H. V. (1990). EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative actovegin: double-blind, placebo-controlled trials. Neuropsychobiology, 24(3), 135-148. https://doi.org/10.1159/000119476 https://pubmed.ncbi.nlm.nih.gov/2135068/
20. Anderer, P., Saletu, B., Semlitsch, H. V., & Pascual-Marqui, R. D. (1998). Electrical sources of P300 event-related brain potentials revealed by low resolution electromagnetic tomography. 2. Effects of nootropic therapy in age-associated memory impairment. Neuropsychobiology, 37(1), 28-35. https://doi.org/10.1159/000026473 https://pubmed.ncbi.nlm.nih.gov/9438269/
21. Talypov, A. E., Ioffe, I.uS., Miatchin, M. I.u, & Kuksova, N. S. (2008). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 108(8), 20-23. https://pubmed.ncbi.nlm.nih.gov/18833103/
22. Demchenko, E. I.u, Kulakova, N. V., Semiglazova, T. A., Golovacheva, A. B., Borodulina, E. V., & Udut, V. V.. (2008). Eksperimental'naia i klinicheskaia farmakologiia, 71(6), 13-15. https://pubmed.ncbi.nlm.nih.gov/19140508/
23. Martynov, M. Y., Bogolepova, A. N., & Yasamanova, A. N. (2021). Endotelial'naya disfunktsiya pri COVID-19 i kognitivnye narusheniya [Endothelial dysfunction in COVID- 19 and cognitive impairment]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 121(6), 93-99. https://doi.org/10.17116/jnevro202112106193 https://pubmed.ncbi.nlm.nih.gov/34283537/
24. Semlitsch, H. V., Anderer, P., Saletu, B., & Hochmayer, I. (1990). Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative actovegin in age-associated memory impairment. Neuropsychobiology, 24(1), 49-56. https://doi.org/10.1159/000119042 https://pubmed.ncbi.nlm.nih.gov/2132641/
25. Derev'yannykh, E. A., Bel'skaya, G. N., Knoll, E. A., Krylova, L. G., & Popov, D. V. (2008). Experience in the use of actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neuroscience and behavioral physiology, 38(8), 873-875. https://doi.org/10.1007/s11055-008-9051-0 https://pubmed.ncbi.nlm.nih.gov/18802768/
26. Schaffler, K., Wauschkuhn, C. H., & Häuser, B. (1991). Study to evaluate the encephalotropic potency of a hemodialysate. Controlled study using electro-retinography and visual evoked potentials under hypoxic conditions in human volunteers (preliminary communication). Arzneimittel-Forschung, 41(7), 699-704. https://pubmed.ncbi.nlm.nih.gov/1772457/
27. Meilin, S., Machicao, F., & Elmlinger, M. (2014). Treatment with actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. Journal of cellular and molecular medicine, 18(8), 1623-1630. https://doi.org/10.1111/jcmm.12297 https://pubmed.ncbi.nlm.nih.gov/24797227/
28. Shul'ginova, A. A., Laskov, V. B., Konoplya, A. I., & Karaulov, A. V. (2016). Eksperimental'naia i klinicheskaia farmakologiia, 79(7), 3-7. https://pubmed.ncbi.nlm.nih.gov/29782737/
29. Mychka, V. B., Khazova, I. E., Gornostaev, V. V., & Sergienko, V. B. (2005). Terapevticheskii arkhiv, 77(10), 20-24. https://pubmed.ncbi.nlm.nih.gov/16320679/
30. Vesel'skiĭ, I. S.h, Sanik, A. V., & Nasonova, T. I. (1995). Diagnostika mikrotsirkuliatorno-reologicheskikh narusheniĭ i ikh korrektsiia u bol'nykh s nachal'nymi proiavleniiami nedostatochnosti krovosnabzheniia mozga [The diagnosis of microcirculatory-rheological disorders and their correction in patients with the initial manifestations of insufficiency of the cerebral blood supply]. Likars'ka sprava, (9-12), 87-89. https://pubmed.ncbi.nlm.nih.gov/8983804/
31. Macheret, I.eL., & Khanenko, N. V. (2002). Medykamentozne likuvannia khvorykh na dystsyrkuliatornu entsefalopatiiu [Drug therapy of patients with dyscirculatory encephalopathy]. Likars'ka sprava, (3-4), 84-87. https://pubmed.ncbi.nlm.nih.gov/12145902/
32. Fomin, A. A., & Pershakov, D. R. (2015). Khirurgia, (8), 54-57. https://doi.org/10.17116/hirurgia2015854-57 https://pubmed.ncbi.nlm.nih.gov/26356060/
33. Orlova, A. I., Sukovatykh, B. S., Artiushkova, E. B., & Gordov, M. I. (2017). Vliianie aktovegina i solkoserila na mikrotsirkuliatsiiu pri kriticheskoĭ ishemii nizhnikh konechnosteĭ v éksperimente [Effect of actovegin and solcoseryl on microcirculation in experimental critical lower limb ischaemia]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 23(1), 29-35. https://pubmed.ncbi.nlm.nih.gov/28574034/
34. Shamalov, N. A., Stakhovskaia, L. V., Shetova, I. M., Efremova, N. M., & Anisimov, K. V. (2010). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 110(9 Pt 2), 13-17. https://pubmed.ncbi.nlm.nih.gov/21462435/
35. Yakupov, E. Z., & Nalbat, A. V. (2015). Pokazateli vegetativnogo gomeostaza kak prediktory individual'nogo riska razvitiya insul'ta i ikh dinamika na fone lecheniya aktoveginom [The measures of autonomic homeostasis as predictors of an individual risk of stroke and their dynamics during therapy with actovegin]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 115(10 Pt 2), 31-42. https://doi.org/10.17116/jnevro201511510231-42 https://pubmed.ncbi.nlm.nih.gov/26977914/
36. Li, W., Guo, A., Sun, M., Wang, J., & Wang, Q. (2021). Neuroprotective Effects of Deproteinized Calf Serum in Ischemic Stroke. Frontiers in neurology, 12, 636494. https://doi.org/10.3389/fneur.2021.636494 https://pubmed.ncbi.nlm.nih.gov/34557139/
37. Kukhtevich, I. I., Aleshina, N. I., & Levashova, O. A. (2014). Aktivnaia neĭroprotektivnaia terapiia ostrogo karotidnogo ishemicheskogo insul'ta sredneĭ stepeni tiazhesti [The active neuroprotective therapy of acute carotid ischemic stroke of moderate severity]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 114(12 Pt 2), 38-42. https://doi.org/10.17116/jnevro201411412238-42 https://pubmed.ncbi.nlm.nih.gov/25726801/
38. Safarova, T. P., Yakovleva, O. B., Sheshenin, V. S., & Gavrilova, S. I. (2018). Metody augmentatsii antidepressivnoĭ terapii v gerontopsikhiatricheskoĭ praktike (on the model of complex therapy s vkliucheniem aktovegina) [Methods of augmentation of antidepressant therapy (on the model of complex therapy with the inclusion of actovegin) in gerontopsychiatric hospital]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 118(6. Vyp. 2), 55-63. https://doi.org/10.17116/jnevro201811806255 https://pubmed.ncbi.nlm.nih.gov/30346435/
39. Konoplya, A. I., Laskov, V. B., & Shul'ginova, A. A. (2015). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 115(11), 28-32. https://doi.org/10.17116/jnevro201511511128-32 https://pubmed.ncbi.nlm.nih.gov/26978048/
40. Skoromets, A. A., & Koval'chuk, V. V. (2007). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 107(2), 21-24. https://pubmed.ncbi.nlm.nih.gov/18379517/
41. Kudriavtsev A. A. (2000). Ostrye narusheniia mozgovogo krovoobrashcheniia pri operatsiiakh na organakh briushnoĭ polosti [Acute cerebrovascular disorders during surgical operations on abdominal organs]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 100(7), 14-17. https://pubmed.ncbi.nlm.nih.gov/10957794/
42. Kurkin, D. V., Bakulin, D. A., Morkovin, E. I., Kalatanova, A. V., Makarenko, I. E., Dorotenko, A. R., Kovalev, N. S., Dubrovina, M. A., Verkholyak, D. V., Abrosimova, E. E., Smirnov, A. V., Shmidt, M. V., & Tyurenkov, I. N. (2021). Neuroprotective action of Cortexin, Cerebrolysin and actovegin in acute or chronic brain ischemia in rats. PloS one, 16(7), e0254493. https://doi.org/10.1371/journal.pone.0254493 https://pubmed.ncbi.nlm.nih.gov/34260655/
43. Astashkin, E. I., Glezer, M. G., Vinokurov, M. G., Egorova, N. D., Orekhova, N. S., Novikova, A. N., ... & Sobolev, K. E. (2013, January). actovegin reduces the ROS level in blood samples of heart failure patients and diminishes necrosis of SK-N-SH human neuroblastoma cells. In Dokl Biol Sci(Vol. 448, No. 1, pp. 57-60). https://www.researchgate.net/profile/Evgeny-Astashkin/publication/303521579_DANBio1301005AstashkinKOR-1/links/574673e108aea45ee856190a/DANBio1301005AstashkinKOR-1.pdf
44. Suchkov, I. A., Mzhavanadze, N. D., Bogachev, V. Y., Bokuchava, M., Kuznetsov, M. R., Lukyanov, Y. V., Kelimbetov, R., Pang, H., & Araslanov, S. A. (2022). Efficacy and safety of actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO). International angiology : a journal of the International Union of Angiology, 41(5), 405-412. https://doi.org/10.23736/S0392-9590.22.04895-7 https://pubmed.ncbi.nlm.nih.gov/36264097/
45. Dittmar, K., & Krause, D. (1977). Erfolge kranken-gymnastischen Intervalltrainings bei Claudicatio intermittens [Success of physiotherapeutic interval training combined with standardized hemoderivative in intermittent claudication (author's transl)]. MMW, Munchener medizinische Wochenschrift, 119(11), 369-372. https://pubmed.ncbi.nlm.nih.gov/403421/
46. Dittmar, K., & Krause, D. (1977). Erfolge kranken-gymnastischen Intervalltrainings bei Claudicatio intermittens [Success of physiotherapeutic interval training combined with standardized hemoderivative in intermittent claudication (author's transl)]. MMW, Munchener medizinische Wochenschrift, 119(11), 369-372. https://pubmed.ncbi.nlm.nih.gov/403421/
47. Pfister, A., & Koller, W. (1990). Therapie der frischen Muskelverletzung [Treatment of fresh muscle injury]. Sportverletzung Sportschaden : Organ der Gesellschaft fur Orthopadisch-Traumatologische Sportmedizin, 4(1), 41-44. https://doi.org/10.1055/s-2007-993596 https://pubmed.ncbi.nlm.nih.gov/2193424/
48. Reichl, F. X., Holdt, L. M., Teupser, D., Schütze, G., Metcalfe, A. J., Hickel, R., Högg, C., & Bloch, W. (2017). Comprehensive Analytics of actovegin® and Its Effect on Muscle Cells. International journal of sports medicine, 38(11), 809-818. https://doi.org/10.1055/s-0043-115738 https://pubmed.ncbi.nlm.nih.gov/28895623/
49. Søndergård, S. D., Dela, F., Helge, J. W., & Larsen, S. (2016). actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. European journal of sports science, 16(7), 801-807. https://doi.org/10.1080/17461391.2015.1130750 https://pubmed.ncbi.nlm.nih.gov/26744809/
50. Belikan, P., Nauth, L., Färber, L. C., Abel, F., Langendorf, E., Drees, P., Rommens, P. M., Ritz, U., & Mattyasovszky, S. G. (2020). Intramuscular Injection of Combined Calf Blood Compound (CFC) and Homeopathic Drug Tr14 Accelerates Muscle Regeneration In Vivo. International journal of molecular sciences, 21(6), 2112. https://doi.org/10.3390/ijms21062112 https://pubmed.ncbi.nlm.nih.gov/32204424/
51. Pavlov O. O. (2009). Klinichna khirurhiia, (1), 32-34. https://pubmed.ncbi.nlm.nih.gov/19670751/
52. Pavlov O. O. (2008). Klinichna khirurhiia, (9), 57-59. https://pubmed.ncbi.nlm.nih.gov/19275037/
53. Lominadze, A. A., & Sharvashidze, N. K. (2006). Georgian medical news, (138), 65-68. https://pubmed.ncbi.nlm.nih.gov/17057302/
54. Fedorovich A. A. (2012). Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvascular research, 84(1), 86-93. https://doi.org/10.1016/j.mvr.2012.03.011 https://pubmed.ncbi.nlm.nih.gov/22497731/
55. Opanasenko, H. B., Bratus', L. V., Havenauskas, B. L., Honchar, O. O., Man'kovs'ka, I. M., Nosar, V. I., & Frantsuzova, S. B. (2013). Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 59(1), 17-24. https://pubmed.ncbi.nlm.nih.gov/23713346/
56. Trofimova, S. V., Atakhanova, L. E., & Akhmedova, E. P. (2008). Advances in gerontology = Uspekhi of gerontology, 21(4), 625-632. https://pubmed.ncbi.nlm.nih.gov/19432215/
57. Krasnov, M. M., Baiandin, D. L., Vorob'eva, O. K., & Klimchenko, I.uG. (1995). Taktika vybora sosudistogo kollektor i sposoba vvedeniia lekarstvennykh veshchestv v metodike vnutriarterial'noĭ infuzionnoĭ terapii organov zreniia [Tactics in choosing a vascular collector and drug administration method in intra-arterial infusion therapy of organs of vision]. Vestnik of ophthalmology, 111(1), 23-27. https://pubmed.ncbi.nlm.nih.gov/7771038/
58. Shkrebets G. V. (2011). Vestnik of ophthalmology, 127(5), 38-41. https://pubmed.ncbi.nlm.nih.gov/22165098/
59. Fedorovich A. A. (2013). Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 19(4), 27-38. https://pubmed.ncbi.nlm.nih.gov/24429557/
60. Beetz, A., Machicao, F., Ried, C., Ruzicka, T., & Michel, G. (1996). Radioprotective effects of a protein-free hemodialysate in human epidermis. Skin pharmacology : the official journal of the Skin Pharmacology Society, 9(3), 197-202. https://doi.org/10.1159/000211416 https://pubmed.ncbi.nlm.nih.gov/8737917/
61. Liu, B., Li, X., Ai, F., Wang, T., Chen, Y., & Zhang, H. (2015). The influence of radiotherapy on IL-2 and IL-6 secretions of mucous membrane epithelial cells of wistar small intestine. Cell biochemistry and biophysics, 71(1), 35-38. https://doi.org/10.1007/s12013-014-0158-3 https://pubmed.ncbi.nlm.nih.gov/25081000/
62. Wang, X. W., Lin, X. Y., Bi, Y. H., & Han, J. Q. (2009). Zhonghua zhong liu za zhi [Chinese journal of oncology]., 31(10), 742-745. https://pubmed.ncbi.nlm.nih.gov/20021825/
63. Gulevsky, A. K., Moiseyeva, N. N., & Gorina, O. L. (2011). Influence of low molecular (below 5 KD) fraction from cord blood and actovegin on phagocytic activity of frozen-thawed neutrophils. Cryo letters, 32(2), 131-140. https://pubmed.ncbi.nlm.nih.gov/21766142/
64. Shevantaeva, O. N., & Kosiuga, I.uI. (2006). Eksperimental'naia i klinicheskaia farmakologiia, 69(2), 40-43. https://pubmed.ncbi.nlm.nih.gov/16845939/
65. Vakhrushev, Y. M., & Lyapina, M. V. (2017). Korrektsiia narusheniĭ funktsional'nogo sostoianiia tonkoĭ kishki kak novoe napravlenie lecheniia bol'nykh s metabolicheskim sindromom [Correction of small bowel function as a new direction for treating patients with metabolic syndrome]. Terapevticheskii arkhiv, 89(8), 43-49. https://doi.org/10.17116/terarkh201789843-49 https://pubmed.ncbi.nlm.nih.gov/28914850/
66. Kuznetsov, M. R., Bogachev, V. I., Sapelkin, S. V., Papysheva, O. V., Neskhodimov, L. A., Khotinskiĭ, A. A., & Mazitova, M. I. (2020). Dopolnitel'nye vozmozhnosti v konservativnom lechenii patsientov s posttromboticheskoĭ bolezn'iu nizhnikh konechnosteĭ [Additional possibilities in conservative treatment of patients with post-thrombotic disease of lower limbs]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 26(1), 31-36. https://doi.org/10.33529/ANGIO2020115 https://pubmed.ncbi.nlm.nih.gov/32240133/
67. Kuznetsov, M. R., Karalkin, A. V., Fedin, A. I., Virganskii, A. O., Kunitsyn, N. V., Kholopova, E. A., & Yumin, S. M. (2015). Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 21(3), 27-35. https://pubmed.ncbi.nlm.nih.gov/26355920/
68. Schubert, J., & Krost, B. (2006). Prävention von Lippen-Kiefer-Gaumen-Spalten. 25 Jahre klinische Erfahrung in der Senkung des Wiederholungsrisikos [Prevention of cleft lip and palate. Reducing risk of recurrence-a 25-year clinical experience]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 10(5), 301-305. https://doi.org/10.1007/s10006-006-0020-x https://pubmed.ncbi.nlm.nih.gov/16944083/
69. Kuznetsov, M. P., Fedin, A. I., Karalkin, A. V., Frolov, K. B., Kunitsin, N. V., Yumin, S. M., Kholopova, E. A., & Knyazev, A. V. (2016). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 116(2), 34-41. https://doi.org/10.17116/jnevro20161162134-41 https://pubmed.ncbi.nlm.nih.gov/27029445/
70. Dong, Z. Y., Yang, S. R., Zhang, J. N., & Yao, Y. Z. (2021). Shanghai kou qiang yi xue = Shanghai journal of dentistry, 30(1), 89-92. https://pubmed.ncbi.nlm.nih.gov/33907787/
71. Wu, S. X., Cui, T. T., Zhao, C., Pan, J. J., Xu, B. Y., Tian, Y., & Cui, N. J. (2010). A prospective, randomized, multi-center trial to investigate actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 97(1), 113-118. https://doi.org/10.1016/j.radonc.2010.08.003 https://pubmed.ncbi.nlm.nih.gov/20826029/
72. Uchkin, I. G., Zudin, A. M., Bagdasarian, A. G., & Fedorovich, A. A. (2014). Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 20(2), 27-36. https://pubmed.ncbi.nlm.nih.gov/24961324/

Protein-free hemodialysate: A natural enhancer for cellular health and regenerative processes

Solcoseryl is a unique medical product derived from protein-free hemodialysate of dairy calves. It is enriched with ingredients commonly found in cells and blood serum. Its main purpose is to increase the delivery of oxygen and glucose to cells, especially when they are deficient in oxygen. Through this action, solcoseryl promotes cellular energetics, supporting the body's natural regeneration processes. In addition, it plays a key role in skin rejuvenation and maintaining the integrity of blood vessels.

Solcoseryl is available in various forms, such as injectable liquid, gel or cream. There is also a special version for oral problems, such as painful gums or lips. People reach for this drug to relieve various skin problems and for oral care.

Benefits of using solcoseryl: Based on medical studies

Solcoseryl has demonstrated efficacy in a variety of conditions - from accelerating wound healing and relieving gingival inflammation to optimizing neurological function. How can solcoseryl be an innovative therapeutic agent in various medical fields?

Benefits of solcoseryl for the brain and nervous system

Solcoseryl has shown promising results in numerous scientific studies that have focused on its potential benefits for brain and nervous system health. From reducing brain damage caused by bleeding to enhancing learning and memory processes in animal models.

Reduced brain damage: Studies show that solcoseryl may be helpful for people experiencing bleeding in the brain caused by a blood vessel rupture, known as an aneurysm. In one study, 300 patients with arterial aneurysms received solcoseryl, while 50 received no treatment. The results showed that the group receiving solcoseryl showed better recovery. These patients achieved better outcomes 30 days after brain injury. They achieved fewer serious health problems and deaths compared to the group not receiving the drug. This suggests that solcoseryl may help alleviate the negative effects of bleeding in the brain caused by ruptured arteries [1].

Preventing nerve ulcers: solcoseryl in combination with Proglumide can effectively prevent nerve ulcers in patients with significant kidney problems. In a scientific study, patients with significant kidney problems after surgery or trauma were given solcoseryl (in combination with Proglumide) as a means of preventing nerve ulcers. The results of the study showed that patients receiving this treatment were less likely to develop ulcers compared to the group that did not receive this drug combination [2].

Modulation of brain activity: an animal study suggests that solcoseryl positively affects brain activity. It was shown that at specific times and doses, the administration of solcoseryl affected the movements and sleep patterns of rats. For example: it reduced sleep time when given 15 minutes before another drug. These results suggest that solcoseryl may have the ability to modulate brain activity and influence certain behaviors [3].

Improving learning and memory: Another study in rats indicates that solcoseryl may have a beneficial effect on learning and memory processes. Solcoseryl was found to improve both the "acquisition" phase of new information and its subsequent recall. For certain tasks, different doses showed specific positive effects, suggesting solcoseryl's potential to enhance brain function related to learning and memory [4].

Helping with cerebral ischemia: solcoseryl combined with acupuncture may benefit cerebral ischemia. An animal study showed that a combination of solcoseryl and acupuncture had better results in reducing symptoms than using each treatment separately. Specifically, this combined approach significantly reduced problems observed in the cerebral ischemia model, such as high rates of neurological deficit and increased water and lactic acid content in the brain [5].

Potential benefits in treating blood circulation problems in the brain

Promising treatment for adverse cerebrovascular conditions:

solcoseryl has been studied in the context of its effects on patients with early or ongoing cerebrovascular problems, conditions related to blood circulation in the brain. The study included 29 patients. Some of them struggled with vegetovascular dystonia, affecting the blood vessels and nervous system, and others with varying degrees of dyscratic encephalopathy, affecting brain function due to blood circulation problems. The results showed a positive effect of solcoseril. Patients experienced fewer and shorter episodes of vegetovascular problems, and reported better general well-being. This suggests that solcoseryl may be a beneficial approach to managing conditions related to blood circulation in the brain [6, 6A].

Significant benefits for cerebrovascular anemia (CVI):

Cerebrovascular anemia, known as CVI, is a condition in which blood supply to the brain is reduced. An extensive study was conducted. It involved 243 patients who received daily injections of solcoseril (2.0 ml each) for 25 days, and this treatment was repeated twice a year. The results showed a marked reduction in neurological symptoms. Patients were also given medications to regulate blood pressure and prevent blood clots. The combination of solcoseril with other drugs resulted in a significant reduction in the patients' risk of deterioration, as well as a reduction in the number of incidents of temporary blood supply disruptions and strokes compared to those treated with standard methods. These findings suggest that solcoseryl may be an important component in the treatment of CVI, enhancing the benefits of other therapies and improving the overall health of patients [7].

As such, solcoseryl may provide relief for patients with blood circulation problems in the brain. Its benefits range from reducing symptoms, improving overall health and lowering the risk of more serious complications. The above results underscore solcoseryl's potential as an effective therapeutic agent for neurological problems.

Healing properties of solcoseryl:

Recent scientific studies indicate that solcoseryl plays a significant role in accelerating and effectively supporting recovery from various types of injuries.

Solcoseryl for eye health:

Solcoseryl is gaining prominence in the field of ophthalmic care, offering a range of benefits for various eye conditions. From dry eyes to corneal damage. The therapy is showing promising results in relieving symptoms and promoting healing. The following are scientific studies that illustrate the potential role of solcoseryl in ocular disorders.

Healing of eye injuries:

A study of the effectiveness of "solcoseryl Eye-Gel" compared to "Cysteine Eye-Gel" for corneal injuries. Solcoseryl proved to be the more effective choice. After treatment with solcoseryl gel, its effect on tissue regeneration and increased cellular oxygen uptake was noted. Over the course of treatment, as many as 63% of patients using solcoseryl saw complete healing of their epithelial injuries, compared to only 53% for Cysteine Eye-Gel. This suggests that solcoseryl accelerates the recovery process after corneal injuries and benefits eye health [17].

Increased moisture and healing of dry eyes:

A comparative study between "solcoseryl eye drops" and "Vitasic eye drops" showed that solcoseryl achieved better results. In participants with corneal erosion and dry eye syndrome, solcoseryl not only accelerated the healing process, but also increased eye moisture. The statistically significant improvement establishes the formulation as a more effective treatment option for these eye conditions [18].

Better healing of corneal injuries with solcoserol:

In a controlled, double-blind study involving 61 patients with corneal injuries, "solcoseryl Eye-Gel" was tested against 2.4% cysteine eye gel. The eyes of patients treated with solcoseryl Eye-Gel not only healed faster, but were also less likely to develop corneal macula temidoj after the healing process was complete [19].

Accelerated corneal healing after foreign body removal with solcoseril:

The double-blind study evaluated the effect of solcoseril on corneal healing, particularly after foreign body removal. Those treated with solcoseril showed faster healing than the control group. In addition, the solcoseril-treated group was less likely to develop corneal opacity. The lack of negative side effects associated with the use of solcoseril underscores its potential for effective corneal healing after foreign body removal [20].

Help for chronic dry eye syndrome:

Solcoseryl has proven to be a versatile solution for a variety of eye problems. In a study involving 18 patients with chronic dry eye syndrome, solcoseryl gel proved extremely helpful. Not only did it promote healing of the corneal surface, but it also increased the transparency of the cornea. Compared to another treatment, i.e. 2,4% ophthalmic gel with cysteine, solcoseryl showed better efficacy, especially in patients with dry keratitis, due to better tolerability [21].

Good for contact lens wearers with dry eyes:

Contact lens wearers often experience discomfort from dry eyes and associated corneal damage. In a study involving contact lens wearers with dry eyes, of the 66 participants, those who added solcoseryl to their treatment along with Corneregel saw significant benefits. Within 7 to 14 days, many noticed corneal healing. For those with more advanced damage, the introduction of solcoseryl further improved the cornea, providing additional comfort for lens wearers. This combination not only resulted in regeneration of the corneal surface, but also had a positive effect on the anterior layer of the eye, providing both health and comfort for lens wearers [22].

Help with vascular problems in the eyes:

For people with vascular problems in their eyes, solcoseryl may prove to be a savior. In a scientific study spanning more than 17 years with 2331 patients, solcoseryl treatment led to increased visual function, improved retinal blood vessel function, and provided lasting improvement. Impressively, the recovery time for patients undergoing solcoserol treatment is reduced [23].

Summary:

In each of these cases, solcoseryl is shown to be a helpful treatment for a variety of eye problems, helping to improve patients' vision and overall well-being.

Solcoseryl for cardiovascular health:

Solcoseryl has shown potential in improving cardiovascular health. A number of studies have shown the beneficial effects of solcoseryl in patients facing a variety of cardiovascular conditions. These range from aiding recovery after heart attacks to treating peripheral vascular disease. The product has demonstrated efficacy and a potential role in comprehensive cardiac care.

Faster recovery after heart attack with solcoseril:

In a study involving 58 patients with acute myocardial infarction, solcoseryl was used to evaluate its effect on recovery. The results were promising: patients treated with solcoseryl reported fewer episodes of angina, suggesting a reduction in heart pain. Those treated with solcoseryl showed faster recovery from CHF symptoms and improved ability to perform physical activity [24].

Calf blood dialysate (solcoseryl/Actovegin) after myocardial infarction:

In another study involving 60 people after myocardial infarction, calf blood dialysate (solcoseryl/Actovegin) lowered the levels of specific enzymes in their blood, such as creatine kinase and aspartate aminotransferase, where both indicate a reduction in cardiac damage. This suggests that calf blood dialysate may offer some potential cardiovascular benefits [25].

Solcoseryl in a multidirectional approach to treating chronic heart disease:

Patients with chronic coronary heart disease (CHD) may benefit from a therapeutic approach involving solcoseryl. A large study involving 349 CHD patients used therapies combining He-Ne laser radiation, alpha-tocopheryl acetate and solcoseryl. Results indicated that solcoseryl, in combination with these therapies, significantly relieved pain and improved exercise tolerance. Importantly, the formulation also showed significant efficacy against arrhythmias, highlighting its potential role in the comprehensive treatment of heart disease [26].

Effects of solcoseryl on vascular atherosclerosis:

For people with chronic atherosclerosis of the lower extremities, calf blood dialysate may offer hope. A study of 158 such patients revealed that after treatment with solcoserol, as many as 93% experienced improvements in quality of life, sustained for at least six months. In addition, minimal doses of aspirin and nicotinic acid were found to be effective as maintenance therapy in between treatment cycles [27].

Treatment of peripheral vascular disease with solcoserol:

Choroba naczyń obwodowych to poważne zaburzenie naczyniowe. Stan pacjentów z tym schorzeniem poprawił się znacznie po leczeniu solcoserylem. Nie tylko objawy i widoczne oznaki choroby uległy poprawie, ale również poziom tlenu, wcześniej obniżony z powodu choroby. Nastąpił również wzrost różnicy między poziomami tlenu tętniczego i żylnego.  Poziom kwasu mlekowego spadł, co wskazuje na rolę solcoserylu w poprawie transportu i wykorzystania tlenu, zwłaszcza w obszarach dotkniętych chorobą [28].

Potential of solcoseryl in the treatment of ulcers:

Reduced time to treat ulcers with aevitum and solcoseril:

A large study involving 105 patients with peptic ulcers used a combination of aevitum and solcoseryl. The methods of administering solcoseryl varied, but the group receiving direct injections experienced rapid healing, with their ulcers completely healed in just 10-12 days, a significant breakthrough [29].

Reduced healing time and recurrence rate with solcoserol and statisol:

Another study, on 300 ulcer patients, used a combination of solcoseril and "statizol." The results were promising, cutting the healing time in half and significantly reducing the recurrence rate of ulcers. The recurrence rate was much lower in the group receiving this combined treatment compared to the control group [30].

Faster recovery from ulcer surgery with solcoseril:

Patients undergoing ulcer surgery and receiving solcoseryl by injection experienced earlier relief from pain, reduced inflammation and smoother recovery. In addition, they were able to be discharged from the hospital 3-5 days earlier than expected, reducing the cost of their stay and speeding up their return to normal life [31].

Solcoseryl appears to play an important role in shortening healing time and reducing ulcer recurrence, a promising prospect for those suffering from the condition.

Better healing in rats with solcoserol and cyclopherol:

Experimental studies on male rats showed that the combination of solcoseril with cyclopherone, an interferon inducer, had promising healing properties. Rats treated with the combination showed better healing of duodenal ulcers compared to those treated with each drug separately [32]. These results suggest the potential of solcoseryl in ulcer management, especially when used in combination with other drugs.

Oral health benefits:

Accelerate wound healing in the oral cavity:

The researchers used a unique dental film, Diplan-denta C, containing solcoseryl, to accelerate healing of surgical wounds on the inside of the cheek. Comparing this to conventional treatments, the Diplan-denta C film accelerated the healing of buccal mucosal injuries, suggesting a potential role for solcoseryl in the healing process [33].

Support for patients with hypertension:

The study examined how "solcoseryl-Denta" cream assists hypertensive patients undergoing oral prosthetic procedures. The use of the cream accelerated the healing of the oral mucosa, which significantly reduced the risk of complications after the procedure [34]. This suggests that solcoseryl may play a role in improving oral health, especially for patients undergoing dental procedures.

A solution for severe gum disease:

In a study with people suffering from a severe form of gum disease, solcoseryl was injected into the gums, showing promising results. There was a significant reduction in inflammation, bleeding and fluid in specific areas of the gums. Although it did not significantly affect tooth mobility or pocket depth, this suggests that the substance may have a beneficial effect on symptoms associated with severe gum disease [35].

Pain-free recovery after gum surgery:

For some bridgework, Solcoseryl Dental Adhesive Paste has proven to be a key component in post-operative care, enabling pain-free recovery [36].

Counteracting dry socket after tooth extraction:

A study that used a combination of gelatin and solcoseryl after tooth extraction aimed to counteract "dry socket," a painful postoperative condition. The group treated with the preparation recorded a significant reduction in the number of cases of dry socket, suggesting a potential role for the substance in preventing this painful post-extraction complication [37].

Musculoskeletal benefits:

Solcoseryl also appears to benefit the musculoskeletal system, particularly bone health and joint pain relief.

Strengthening the femur:

A study in young rats suggests that solcoseryl may affect the strength of the femur, increasing its toughness. In addition, it appears to counteract the debilitating effects of some drugs, highlighting its potential role as a bone-strengthening substance [38].

Pain relief for osteoarthrosis of the knee:

In a study on patients with knee osteoarthrosis, injections of solcoseryl/actovegin directly into the knee joints resulted in a decrease in pain. Patients experienced an average decrease in VAS scores and an average reduction in pain scores. The lack of reported side effects suggests that this treatment may not only be effective, but also safe. Nevertheless, further studies are needed to confirm these promising results [39].

Improving bone formation around dental implants

The process of osseointegration is crucial for the successful placement of dental implants. There has been some interesting research on the potential role of solcoseryl in this area. Conducted on rabbits, the study focused on combining calf blood dialysate with a capacitively coupled electric field (CCEF) technique, aiming to explore the possibility of increasing bone growth around dental implants. The results are promising, as bone formation and strength in the implant area were significantly improved using both solcoseril and CCEF. These results suggest that combining these two treatments can significantly improve the success of dental implants [40].

Based on these observations, it appears that solcoseryl may play a key role in promoting musculoskeletal health. Its potential not only to strengthen bones, but also to relieve joint pain and improve the effectiveness of dental implants makes it a versatile ingredient in the orthopedic and dental therapy fields.

Solcoseryl in the treatment of various medical conditions

Scientific studies show the potential of solcoseryl in the treatment of a variety of medical conditions, from lower extremity preganglion to severe head injuries. Its various mechanisms of action include improving chemical processes in the body, reducing inflammation, promoting tissue healing and potentially protecting against tissue damage.

1. Treatment of preganglion of the lower limb

Gangrene, resulting from ischemia and infection, poses a serious threat to the body's tissues. In the study conducted - solcoseryl applied topically to the affected areas accelerated the healing process and promoted the regeneration of tissues affected by gangrene. The results were promising, with the group using solcoseryl achieving significantly better results compared to the placebo group. The treatment showed efficacy through noticeable improvements in the early symptoms of gangrene, such as skin color changes, pain and swelling in the lower extremities [41].

2. Support for severe head injuries

Solcoseryl has been used in cases of severe head trauma, particularly closed craniocerebral injuries. Administered intravenously in conjunction with antioxidant therapy, it worked by increasing oxygen utilization in damaged brain tissue. In combination with antioxidants, the drug directly influenced inflammatory processes, resulting in significant patient benefits, such as improved neurological status and stabilization of blood pressure [42].

3. Help treat leg ulcers in patients with sickle cell anemia

Sickle cell anemia is characterized by distorted red blood cell morphology, which can lead to various complications, including ulcers. A study conducted on patients with sickle cell anemia showed that topical application of solcoseryl to ulcers resulted in visible healing. The mechanism of action of solcoseryl, based on promoting cellular regeneration and wound healing, contributed to a significant improvement in the condition of patients with the disease [43].

4. Potential in the treatment of chronic bronchitis

In patients with chronic bronchitis, the combination of solcoseryl with other treatments has shown efficacy in improving symptoms and certain biochemical markers associated with the disease. Acting by increasing oxygen delivery and utilization in the lungs, solcoseryl helped relieve symptoms and made positive changes in biochemical markers associated with chronic bronchitis. These findings suggest the potential of solcoseryl to increase the efficacy of overall bronchitis treatment [44].

5. Protection against liver damage

Liver damage can lead to serious conditions such as liver fibrosis and cancer. In a study on protection against liver damage, a protein-free calf blood extract (solcoseryl/actovegin) was likely administered orally to mice. The results suggest that the compound protects cells and promotes liver cell regeneration, highlighting its potential benefits in liver protection in humans as well [45].

6. Positive effects in late pregnancy

In cases of chronic placental insufficiency in late pregnancy, solcoseryl has shown the potential to increase estrogen excretion, a key hormone during pregnancy [46]. Taking solcoseryl intravenously or orally, tailored to the stage of pregnancy and degree of placental insufficiency, led to a significant increase in estrogen secretion, which may be key to maintaining a healthy pregnancy [46].

7. Management of chronic placental insufficiency

In cases of chronic placental insufficiency, which can lead to inadequate blood flow to the fetus, solcoseryl administered intravenously helped increase placental blood flow to support nutrient delivery. Dosage was adjusted according to the progress of the pregnancy and the degree of insufficiency. The results suggest that the use of solcoseryl may improve placental function, which is important in maintaining a healthy pregnancy [47].

8. Management of oxidative stress in pregnancy complications

Oxidative stress in pregnancy complications can adversely affect the health of mother and baby. Solcoseryl, administered orally or intravenously in pregnant women with a diagnosis of intrauterine growth retardation (IUGR), has been used to manage oxidative stress. Dosage was adjusted according to the diagnosis and degree of IUGR. Solcoseryl balances oxidative processes, which led to a significant reduction in oxidative stress markers in pregnant women with IUGR [48].

Possible mechanisms of action of solcoseryl

solcoseryl exhibits a complex mechanism of action that makes it a versatile therapeutic agent with applications in various medical conditions. Derived from a protein-free hemodialysate, its main function includes enhancing tissue regeneration and improving oxygen utilization by cells. Below are some of the key areas in which solcoseryl shows positive effects:

1. Neurological Status:

Solcoseryl helps minimize permanent damage from brain hemorrhages.

Modulates central nervous system activity, improving outcomes in cerebrovascular disease.

Reduces the risk of disease progression and transient ischemic attacks in cerebrovascular insufficiency.

Positively affects learning and memory in animal models.

2. Healing of the Gastrointestinal System:

Effective in accelerating epithelial cell regeneration in corneal injuries, gummy wounds and deep wounds.

3. Cardiovascular Conditions and Peripheral Vascular Diseases:

It contributes to improved hemodynamics.

Supports faster recovery from circulatory failure.

4. Interaction with Other Treatments:

Increases interferon responses.

Supports antioxidant defense.

5. Applications in Wound Care:

Effective in accelerating epithelial cell regeneration in various types of wounds.

6. Regulation of Gene Expression and Signaling Pathways:

Increases the expression of specific genes and intracellular signaling pathways.

Solcoseryl also has a strong safety profile, making it a well-tolerated therapeutic option. Side effects, such as itching or burning sensations, are minimal. However, it is worth emphasizing that these observations are based on studies, and further research is needed to confirm these properties.

Dosage of solcoseryl in various conditions

Here is information on the dosage of solcoseril in various studies and medical conditions:

1. Gastroduodenal Ulcers:

Dose: 10 ml intravenous injection in 5% glucose solution every other day for six days.

This is followed by intramuscular injections of 5 ml for another 4-5 days.

2. Advanced Gum Disease:

Participants: 26 patients aged 18 to 57 years.

Dosage: 30 ampoules of 2 ml solcoseryl injections directly into the gums at various intervals.

3. Knee Joint Degeneration:

Participants: 17 people with knee osteoarthritis.

Dosage: No details on solcoseryl concentration and volume are available.

4. Healing Wounds in Rats:

Comparison of solcoseryl 10% gel with other healing substances.

5. Activity in the Central Nervous System in Rats:

Doses ranging from 0.5 to 2.0 ml/kg affected behavior differently depending on timing and concurrent therapies.

6. Learning and Memory in Rats:

Doses of about 1.0 to 1.25 ml/kg optimized central nervous system functions related to learning and memory.

7. Cerebrovascular Insufficiency:

Intravenous doses of 2.0 ml daily for 25 days led to significant improvements in neurological symptoms.

8. Corneal Damage:

A solcoseryl gel containing 8.3 mg of protein-free dialysate per gram of gel was used.

9. Treatments for the Mucosa and Gums:

Solcoseryl Dental adhesive paste applied three times a day for 7-10 days for painless healing of the donor site.

10. Bone Forming Around Dental Implants:

An intravenous dose of 2 ml/kg, along with other treatments, led to significant improvements in new bone formation.

11. Chronic placental insufficiency:

Patients received 2 doses of 250 ml of protein-free calf blood dialysate (solcoseryl) for 9 days.

It is clear that the use of solcoseril is diverse, but it should be used under medical supervision, optimized for the specific condition and tailored to the patient's needs. It is advisable to consult a doctor to adjust the dosage and form of administration accordingly, depending on the specifics of the medical case.

Dosage forms of solcoseryl

Solcoseryl is available in various forms to meet a variety of medical needs. The main dosage forms of solcoseryl are listed below:

1. Gel/Gelatin solcoseryl:

Use: Mainly used for wound care, especially moist and wet wounds.

Healing Phase: Most often in the initial phases of wound healing.

2. Solcoseryl ointment:

Use: Suitable for dry wounds, it promotes tissue regeneration and protects the wound from external factors.

Healing Phase: Used in the later phases of wound healing.

3. Solcoseryl Adhesive Paste:

Purpose: Specially designed for oral use, it helps heal wounds and ulcers in the mouth.

Adhesive Properties: Holds in place to provide long-lasting relief and promote healing.

4. Solcoseryl injection:

Use: Increases tissue regeneration and oxygen utilization by cells.

Administration: Intramuscular, intravenous or directly into specific sites, depending on the conditions being treated.

5. Solcoseryl Gel:

Use: Promotes faster wound healing and tissue regeneration.

Features and Benefits: Effective in external wound healing, eye care, dentistry and regeneration of various tissues.

Conclusions:

Each form of solcoseryl is tailored to a specific application, providing targeted and effective treatment.

Before using any form of solcoseril, it is recommended to consult a medical professional to determine the appropriate form and treatment regimen for your particular case.

Solcoseryl gel is a versatile solution that speeds up the healing process and is easily tolerated, making it a popular choice in various medical fields.

Solcoseryl injection: summary based on scientific studies

Solcoseryl injection is an innovative medical formula developed to enhance tissue regeneration and accelerate the healing process in various clinical situations. Here is a general overview of its key features based on scientific research:

Cellular oxygenation:

Solcoseryl works by increasing oxygen uptake by cells, which promotes accelerated healing processes in the body.

Broad usability:

It is used in a variety of medical situations, from trauma management to post-surgical recovery, making it versatile in application.

Versatile administration:

The injection can be administered in a variety of ways, including intramuscularly, intravenously or directly into specific sites, adapting to the specifics of medical needs.

Tissue regeneration:

It promotes effective tissue repair, which is particularly valuable in situations where there is a need for accelerated healing.

Safe use:

Developed according to strict quality standards, designed for safety and effectiveness. However, use under the supervision of health professionals is recommended.

Extensively researched:

Solcoseryl has been the subject of various scientific studies, which confirms its reliability and effectiveness in the medical community.

Pain and inflammation management:

In addition to its ability to heal, it can also help reduce pain and inflammation in certain conditions.

Solcoseryl injection is an established and well-studied medical solution that is known for its ability to support and accelerate the body's natural healing processes.

Solcoseryl Ointment: Summary on the Basis of Scientific Research

Solcoseryl ointment, a topical therapeutic agent, is recognized for its wound-healing and tissue-regenerating properties. Below are some of the key features of solcoseryl ointment based on scientific studies:

Wound Healing:

Solcoseryl ointment is designed to speed up the wound healing process, reducing the time it takes for wounds to fully heal. Studies confirm its effectiveness for various types of wounds.

Tissue Regeneration:

In addition to superficial wounds, the ointment promotes the regeneration of deeper skin tissues. This property is particularly valuable in the treatment of various skin conditions.

Origins:

solcoseryl, being a derivative of protein-free calf blood extract, has regenerative properties, which further emphasizes its natural character.

Moisture Barrier:

It acts as an effective moisture barrier, keeping wounds in a suitable moist environment, which promotes the healing process. At the same time, it protects against external irritants.

Versatility:

The ointment has been successfully used in various studies and treatment regimens, covering both minor skin abrasions and more serious skin conditions. This confirms its versatility in a variety of clinical settings.

Security Profile:

It has a favorable safety profile, but awareness of potential allergic reactions or interactions is always recommended. Consultation with a healthcare professional is recommended before use.

Ease of Application:

Being available as an ointment, it makes it easy to apply to affected areas, and can be used under bandages or dressings as needed.

Remember, it is always advisable to consult with health care professionals before using solcoseryl ointment to make sure it is appropriate for your specific condition and individual needs.

Dosage and Administration of Solcoseryl Ointment: Summary.

The dosage and administration of solcoseryl ointment usually depends on the type of wound and its severity. Below is a general summary of dosage and application recommendations:

Purpose:

Solcoseryl ointment is designed for topical application directly to the wound.

Wound Preparation:

Before applying the ointment, it is necessary to thoroughly clean the wound with a disinfectant solution.

Trophic Ulcers and Purulent Infections:

In cases of trophic ulcers or wounds with purulent infection, it may be necessary to perform preliminary surgical treatment before using solcoseryl® ointment.

Application to Dry Wound:

Solcoseryl® ointment is specially formulated for dry (non weeping) wounds.

It should be applied in a thin layer to the cleaned surface of the wound. This can be done 1-2 times a day.

Usage Under the Bandages:

If necessary, the ointment can be used under bandages.

Duration of Treatment:

Treatment with solcoseryl ointment should be continued until the wound is fully healed, epithelialization is achieved and elastic scar tissue is formed.

Application of Additional Forms of solcoseryl:

In cases of significant trophic damage to the skin and soft tissues, intravenous forms of solcoseril are also recommended along with an ointment.

Keep in mind that it is necessary to consult with a healthcare professional before starting treatment to adjust the dosage regimen to the patient's specific needs and the type and severity of the wound. These recommendations are general, and individual cases may require adjustments.

Solcoseryl Paste: Based on Scientific Research.

Specifically designed for oral use, solcoseryl Adhesive Paste demonstrates a number of benefits for tissue healing and regeneration. Below are the key features of solcoseryl paste:

Oral Tissue Healing:

The paste promotes rapid healing of injuries or wounds in the oral cavity, especially post-surgical wounds of the buccal mucosa.

Pain Relief:

Patients report a reduction in discomfort or pain, especially after surgeries, which can be attributed to the soothing properties of the paste.

Adhesive Properties:

The adhesive properties of the paste allow it to firmly adhere to the mucous membranes in the mouth, ensuring long-lasting contact and effective delivery of active ingredients to the affected area.

Security:

By forming a protective layer over wounds or injuries, the paste protects them from further irritation, especially from food, drink or movement in the mouth.

Calf Blood Origins:

solcoseryl, the main ingredient in the paste, is derived from protein-free calf blood extract, which contributes to its regenerative properties and accelerates tissue repair.

Versatile Application:

Although designed for oral use, the paste's benefits extend to a variety of oral conditions, from surgical wounds to ulcers or mouth ulcers.

An addition to Other Therapies:

The paste can be used in combination with other therapies or medications, enhancing the overall healing process, as shown in some studies where it was combined with other dental solutions.

It is always important to consult your dentist or health care professional before using solcoseryl toothpaste to make sure it is appropriate for your specific condition and individual needs.

Solcoseryl Infusion: On the Basis of Scientific Research

Solcoseryl, which is a deproteinized hemodialysate from calf blood, is designed to improve oxygen delivery and utilization in areas of the body with limited blood flow. Key aspects of solcoseryl infusion include:

Stimulation of Cellular Respiration and Metabolism:

Solcoseryl stimulates cellular respiration and metabolism, which contributes to accelerated healing and tissue regeneration.

Improving Oxygen Delivery:

The product aims to improve oxygen delivery in oxygen-limited areas of the body, which is important for healing processes.

Improving Tissue Regeneration:

Solcoseryl promotes faster tissue regeneration, making it valuable in situations that require an intensive healing process.

Solcoseryl infusion has been extensively researched, which reinforces its credibility as an effective solution for supporting regenerative processes in the body.

Applications of Solcoseryl Infusion:

Solcoseryl infusion is used for a variety of conditions, including:

Peripheral Vascular Diseases:

Solcoseryl can be used to support the treatment of peripheral vascular diseases that involve blood vessels outside the heart and brain area.

Diabetic Polyneuropathy:

In cases of diabetic polyneuropathy, which is damage to peripheral nerves associated with diabetes, infusion of solcoseryl can help improve nerve function.

Conditions Associated with Blood Flow Disorders or Ischemic Events:

Infusion of solcoseryl can be used in conditions associated with blood flow disorders, as well as ischemic events, to promote tissue repair.

Purpose of Solcoseryl Infusion:

The purpose of administering solcoseril by infusion is:

Tissue Repair Support:

solcoseryl works at the cellular level to promote tissue repair processes, which is important for various diseases.

Increasing Oxygenation:

By increasing oxygen delivery to cells, solcoseryl contributes to increased oxygenation, which can positively affect tissue function and health.

Important Notes:

Infusion of solcoseryl should be administered under the supervision and direction of a qualified medical professional.

The appropriateness of infusions for a particular patient should be determined on the basis of a thorough medical evaluation.

Summary:

Solcoseryl appears to be a versatile drug with a wide range of applications, covering different areas of medicine. Studies suggest that it may have benefits in improving brain function, accelerating wound healing, supporting eye health, and positively impacting heart health. It is a substance that appears to have the potential to help in many different areas of health, making it a broad-spectrum tool in medical practice.

Disclaimer

This article was written for educational purposes and is intended to raise awareness of the substance being discussed. It is important to note that the substance discussed is a substance, not a specific product. The information contained in the text is based on available scientific research and is not intended to serve as medical advice or promote self-medication. The reader should consult any health and treatment decisions with a qualified health professional

References

1. Dziak, L. A., & Golik, V. A. (2001). Opyt primeneniia "Solkoserila" v lechenii bol'nykh s

tserebral'nym krovoizliianiem [Experience gained with Solcoseryl as treatment of patients with

cerebral   hemorrhage]. Likars’ka   sprava,   (4),   162–168.

https://pubmed.ncbi.nlm.nih.gov/11692704/

2. Bouletreau, P., Petit, P., & Motin, J. (1976). Ulcère de stress et insuffisance rénale aigüe

post-opératoire. Tentative de traitement préventif par Solcoseryl et proglumide [Stress ulcer

and   acute   postoperative   renal   insufficiency.   An   attempt   at   preventive   treatment   with

Solcoseryl   and   proglumide]. Annales   de   l’anesthesiologie   francaise, 17(5),   585–590.

https://pubmed.ncbi.nlm.nih.gov/10798/ 

3. Braszko, J. J., Winnicka, M. M., & Wisniewski, K. (1996). Solcoseryl stimulates behavioral

activity   of   rats. Acta   physiologica   Hungarica, 84(1),   63–72.

https://pubmed.ncbi.nlm.nih.gov/8993676/

4. Winnicka, M. M., Braszko, J. J., & Wisniewski, K. (1996). Solcoseryl improves learning and

memory   in   rats. Acta   physiologica   Hungarica, 84(1),   55–62.

https://pubmed.ncbi.nlm.nih.gov/8993675/

5. Wang, Y. M., Gao, J. H., Yu, X. C., Wang, S. X., & Wang, H. X. (2009). Zhen ci yan jiu =.

Acupuncture research, 34(1), 9-12. https://pubmed.ncbi.nlm.nih.gov/19526800/

6. Rudenko, A. I.u, & Bashkirova, L. M. (2003). Solkoseryl-novyĭ zasib patohenetychnoho

likuvannia khvorykh z paroksyzmal'nymy stanamy pry sudynniĭ patolohiï holovnoho mozku

[Solcoseryl-new preparation for the pathogenetic treatment of patients with paroxysmal

forms   of   cerebrovascular   pathology]. Likars’ka   sprava,   (7),   110–113.

https://pubmed.ncbi.nlm.nih.gov/14723151/

6A. Kurako, I.uL., Gertsev, N. F., Gertsev, V. N., Vishnevskiĭ, V. S., Stoianov, A. N., &.

Chemeresiuk, I. G. (2004). Predvaritel'nye dannye ob opyte primeneniia malykh doz

solkoserila v lechenii bol'nykh distsirkuliatornoĭ éntsefalopatieĭ [Preliminary data on the

application   of   low   dose   solcoseril   for   the   treatment   of   patients   with   dyscirculatory

encephalopathy]. Likars’ka   sprava,   (1),   79–80.

https://pubmed.ncbi.nlm.nih.gov/17051721/

7. Chukanova, E. I., & Bogolepova, A. N. (2007). Zhurnal nevrologii i psikhiatrii imeni S.S.

Korsakova, Suppl 21, 57-64. https://pubmed.ncbi.nlm.nih.gov/18927981/

8. Nam, S. M., & Maeng, Y. S. (2019). Wound Healing and Mucin Gene Expression of Human

Corneal   Epithelial   Cells   Treated   with   Deproteinized   Extract   of   Calf   Blood. Current   eye

research, 44(11),   1181–1188.  https://doi.org/10.1080/02713683.2019.1633360

https://pubmed.ncbi.nlm.nih.gov/31204524/

9. Studer O. (1984). A comparative clinical study of Solcoseryl Eye-Gel and Cysteine Eye-Gel.

2.4% in the treatment of foreign-body injuries of the cornea. Ophthalmic research, 16(3),

179–184. https://doi.org/10.1159/000265314 https://pubmed.ncbi.nlm.nih.gov/6472796/

10. Dymkowska, W., & Malarewicz, A. (1980). Anwendung der Fluoreszenzmikroskopie in der

zytochemischen   Bewertung   der   Wundheilung   nach   Gingivektomie   [Use   of   fluorescence

microscopy   in   the   cytochemical   evaluation   of   wound   healing   after

gingivectomy]. Stomatologie   der   DDR, 30(4),   261–269.

https://pubmed.ncbi.nlm.nih.gov/6161451/

11. Wilmink, J. M., Stolk, P. W., van Weeren, P. R., & Barneveld, A. (2000). The effectiveness of

the   haemodialysate   Solcoseryl   for   second-intention   wound   healing   in   horses   and

pon. Journal of veterinary medicine. A, Physiology, pathology, clinical medicine, 47(5),

311–320.  https://doi.org/10.1046/j.1439-0442.2000.00287.x

https://pubmed.ncbi.nlm.nih.gov/10932527/

12. Imran, H., Ahmad, M., Rahman, A., Yaqeen, Z., Sohail, T., Fatima, N., Iqbal, W., & Yaqeen,
13. S. (2015). Evaluation of wound healing effects between Salvadora persica ointment and

Solcoseryl jelly in animal model. Pakistan journal of pharmaceutical sciences, 28(5), 1777-.

1780. https://pubmed.ncbi.nlm.nih.gov/26408876/
1781. Abakarova D. S. (2004). Primenenie novoĭ solkoserilsoderzhashcheĭ plenki Diplen-denta C.

pri lechenii travm slizistoĭ obolochki rta [Use of new solcoseryl-containing Diplan-denta C film

in   the   treatment   of   injuries   of   the   buccal   mucosa]. Stomatologiia, 83(4),   33–36.

https://pubmed.ncbi.nlm.nih.gov/15340302/

14. Pavliuk, B., Stechyshyn, I., Kramar, S., Chubka, M., & Hroshovyi, T. (2021). The effect of gel

"Xeliogel" at the stages of the regeneration of aseptic burn wound in the experiment. Polish

merkuriusz   lekarski   :   organ   Polskiego   Towarzystwa   Lekarskiego, 49(293),   352–355.

https://pubmed.ncbi.nlm.nih.gov/34800022/

15. Miyaji, H., Sakurai, H., Kikawada, M., Yamaguchi, K., Kimura, A., Fujiwara, T., Imada, N.,

Imai, M., Iwamoto, T., & Takasaki, M. (2005). Nihon Ronen Igakkai zasshi. Japanese journal

of   geriatrics, 42(1),   90–98.  https://doi.org/10.3143/geriatrics.42.90

https://pubmed.ncbi.nlm.nih.gov/15732367/

16. Ibishov K. G. (1999). Chrezdrenazhnaia zakrytaia ul'trazvukovaia sanatsiia briushnoĭ polosti v

profilaktike i lechenii infektsionnykh oslozhneniĭ ognestrel'nykh raneniĭ zhivota [Transdrainage

closed   ultrasonic   cleansing   of   the   abdominal   cavity   in   the   prevention   and   treatment   of

infectious   complications   in   abdominal   gunshot   wounds]. Vestnik   khirurgii   imeni   I.   I.

Grekova, 158(2), 40-42. https://pubmed.ncbi.nlm.nih.gov/10368889/

17. Studer O. (1984). A comparative clinical study of Solcoseryl Eye-Gel and Cysteine Eye-Gel.

2.4% in the treatment of foreign-body injuries of the cornea. Ophthalmic research, 16(3),

179–184. https://doi.org/10.1159/000265314 https://pubmed.ncbi.nlm.nih.gov/6472796/

18. Krannig, H. M., Rohde-Germann, H., & Straub, W. (1989). Therapy of corneal erosions and

’dry   eye’   with   Solcoseryl   and   Vitasic   eye   drops. Ophthalmologica.   Journal   international

d’ophtalmologie.   International   journal   of   ophthalmology.   Zeitschrift   fur

Augenheilkunde, 199(2-3),   100–105.  https://doi.org/10.1159/000310024

https://pubmed.ncbi.nlm.nih.gov/2587017/

19. Erbe, W., Herrmann, R., Körner, W. F., Rohde-Germann, H., & Straub, W. (1984). Our

experience with Solcoseryl Eye-Gel in the treatment of corneal lesions. A randomised double-

blind   study   (with   1   color   plate). Ophthalmologica.   Journal   international   d’ophtalmologie.

International   journal   of   ophthalmology.   Zeitschrift   fur   Augenheilkunde, 188(1),   1–4.

https://doi.org/10.1159/000309336 https://pubmed.ncbi.nlm.nih.gov/6366684/

20. Haydon P. (1983). Die Wirkung von Solcoseryl Augen-Gel in Kombination mit Neomycin und

Bacitracin auf die Heilung von Hornhautläsionen nach Fremdkörperentfernung [The effect of

Solcoseryl eye gel in combination with neomycin and bacitracin on the healing of corneal

lesions after foreign body removal]. Klinische Monatsblatter fur Augenheilkunde, 183(3), 213-.

215. https://doi.org/10.1055/s-2008-1054907 https://pubmed.ncbi.nlm.nih.gov/6358645/
216. Krzystkowa, K. M.,   Hydzikowa,   M.,   &   Szpytma,   R.   (1991).   Podwójna   ślepa   próba   z

use of solcoseryl eye gel and 2.4% cysteine eye gel in patients with

keratitis   chronica   recidivans   i   keratitis   sicca   [Double-blind   method   of   using   solcoseryl

ophthalmic gel and 2,4% cysteine in patients with chronic recurrent keratitis

and keratitis sicca]. Eye Clinic, 93(6), 162-163. https://pubmed.ncbi.nlm.nih.gov/1942917/

22. Egorova, G. B., Mitichkina, T. S., & Shamsudinova, A. R. (2014). Vestnik oftalmologii, 130(2),

59-67. https://pubmed.ncbi.nlm.nih.gov/24864502/

23. Eliseeva, E. G., Vorob'eva, O. K., & Astaf'eva, N. V.. (1999). Primenenie solkoserila dlia

lecheniia sosudistoĭ pathologii glaznogo dna [Therapy of fundus oculi vascular pathology by

solcoseryl]. Vestnik oftalmologii, 115(6), 37-38. https://pubmed.ncbi.nlm.nih.gov/10665289/

24. Leshchinskiĭ, L. A., Pimenov, L. T., Kalinina, S. A., & Kolodkin, D. E. (1990). Kursovoe

primenenie   solkoserila   v   kompleksnom   lechenii   i   i   vnutrigospital’noĭ   reabilitatsii   bol’nykh

infarctom myocardium [Administration of solcoseryl in the complex treatment and intrahospital

rehabilitation   of   patients   with   myocardial   infarction]. Kardiologiia, 30(4),   37–40.

https://pubmed.ncbi.nlm.nih.gov/2203929/

25. Moczurad, K. W., Weiner, M., & King, W. (1992). A clinical evaluation of the effect of calf

blood   dialysate   on   the   course   of   acute   myocardial   infarction. Clinical   trials   and   meta-

analysis, 28(1), 13-21. https://pubmed.ncbi.nlm.nih.gov/10148188/

26. Leshchinskii, L. A., Odnopozov, I. I., Valeeva, R. M., Kochubeeva, O. V., Samartsev, D. B.,

Tubylova, N. A., & Mul'manovskii, B. L. (1995). Opyt primeneniia gelii-neonovogo lazernogo

oblucheniia i kompleksnoi terapii na ego osnove pri infarkte mickarda i drugikh formakh IBS

[Experience in using helium-neon laser irradiation alone and in the combined therapy of

myocardial   infarct   and   other   forms   of   IHD]. Terapevticheskii   arkhiv, 67(12),   13–17.

https://pubmed.ncbi.nlm.nih.gov/8820046/

27. Luk'ianov, I.uV., Shlomin, V. V., Sokurenko, G. I.u, Didenko, I.uP., Orlov, N. N., Kondrat'ev,
28. M., & Batalin, I. V. (2000). Otsenka éffektivnosti vnutrivennoĭ monoterapii preparatom.

"Solkoseril" u bol'nykh s obliteriruiushchim aterosklerozom sosudov nizhnikh konechnosteĭ.

[An assessment of the efficacy of intravenous monotherapy with the preparation solcoseryl in

patients  with  arteriosclerosis  obliterans  of  the  vessels  of  the  lower  extremities]. Vestnik

khirurgii imeni I. I. Grekova, 159(3), 81–84.  https://pubmed.ncbi.nlm.nih.gov/10983350/

28. Rossano, C., Weiner, M., & Haigis, E. (1990). Clinical, blood gas, and lactate changes in the

course of the treatment of peripheral vascular disease with a hemodialysate. Arzneimittel-

Forschung, 40(11), 1195-1200. https://pubmed.ncbi.nlm.nih.gov/2085330/

29. Granov, A. M.,   Aiskhanov,   S.   K.,   Nikolaev,   L.   I.,   &   Smirnova,   N.   A.   (1989).   Kliniko-

endoskopicheskaia   otsenka   éffektivnosti   lecheniia   neoslozhnennykh   iazv   zheludka   i

dvenadtsatiperstnoĭ kishki pri mestnom primenenii solkoserila i aevita [Clinico-endoscopic

evaluation of the effectiveness of the treatment of uncomplicated gastroduodenal ulcers after

Local administration of solcoseryl and aevit]. Vestnik khirurgii imeni I. I. Grekova, 144(12), 12-.

13. https://pubmed.ncbi.nlm.nih.gov/2700609/
14. Tsarev, N. I., & Krasnykh, A. M. (1989). Lechebnaia éndoskopiia v kompleksnoĭ terapii.

bol'nykh s khronicheskoĭ gastroduodenal'noĭ iazvoĭ [Therapeutic endoscopy in the complex

treatment   of   patients   with   chronic   gastroduodenal   ulcer]. Vestnik   khirurgii   imeni   I.   I.

Grekova, 142(3), 28-31. https://pubmed.ncbi.nlm.nih.gov/2665305/

31. Fomin, P. D., Zaplavskiĭ, A. V., Ivanchov, P. V., Peresh, E. E., Lissov, A. I., & Tikhonenko, A.
32. (1998). Effektivnost’   primeneniia   solkoserila   posle   operatsii   po   povodu   ostrogo

krovotecheniia   iz   gastroduodenal’noĭ   iazvy   [Effectiveness   of   the   use   of   solcoseryl   after

surgery   of   acute   hemorrhage   in   gastroduodenal   ulcer]. Klinichna   khirurhiia,   (12),   6–8.

https://pubmed.ncbi.nlm.nih.gov/10077934/

32. Bul'on, V. V., Khnychenko, L. K., Sapronov, N. S., Kuznetsova, N. N., Anikin, V. B., arinenko,
33. I.u, Kovalenko,   A.   L.,   &   Alekseeva,   L.   E.   (2001).   Tsikloferon   v   terapii   iazvy

dvenadtsatiperstnoĭ   kishki   u   krys   [Cycloferon   in   treating   duodenal   ulcers   in

rats]. Eksperimental’naia   i   klinicheskaia   farmakologiia, 64(6),   41–44.

https://pubmed.ncbi.nlm.nih.gov/11871237/

33. Abakarova D. S. (2004). Primenenie novoĭ solkoserilsoderzhashcheĭ plenki Diplen-denta C.

pri lechenii travm slizistoĭ obolochki rta [Use of new solcoseryl-containing Diplan-denta C film

in   the   treatment   of   injuries   of   the   buccal   mucosa]. Stomatologiia, 83(4),   33–36.

https://pubmed.ncbi.nlm.nih.gov/15340302/

34. (2014). Georgian medical news, (229), 29-32. https://pubmed.ncbi.nlm.nih.gov/24850602/
35. Jedrzejewska, T., Balczewska, E., Peterson, R., Urbaniak, B., & Ostrowska, B. (1990). Evaluation of

Clinical trials of solcoseryl in the treatment of appendage diseases [Clinical trials of solcoseryl in the treatment

of   parodontium   diseases]. Czasopismo   stomatologiczne, 43(6),   366–370.

https://pubmed.ncbi.nlm.nih.gov/2104369/

36. Bakalian V. L.   (2009). Georgian   medical   news,   (172-173),   39–42.

https://pubmed.ncbi.nlm.nih.gov/19644187/

37. Schatz, J. P.,   Fiore-Donno,   G.,   &   Henning,   G.   (1987).   Fibrinolytic   alveolitis   and   its

prevention. International   journal   of   oral   and   maxillofacial   surgery, 16(2),   175–183.

https://doi.org/10.1016/s0901-5027(87)80127-3  https://pubmed.ncbi.nlm.nih.gov/3110316/

38. Nadulska, A. N. N. A., Klukowska, L. I. D. I. A., & Dyba, S. T. E. F. A. N. (2000, January). The

influence of solcoseryl and vincristine on the mechanical strength of the femur shaft in young

rats. In Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina (Vol. 55, pp. 189-.

192). http://bc.umcs.pl/Content/43265/czas4054_55_2000_29.pdf

39. Kuptniratsaikul, V., &   Kuptniratsaikul,   S.   (2004).   Intra-articular   injection   of   deproteinized

Hemodialysate in osteoarthritis of the knee: a case-series. Journal of the Medical Association

of   Thailand   =   Chotmaihet   thangphaet, 87(1),   100–105.

https://pubmed.ncbi.nlm.nih.gov/14971542/

40. Ochi, M., Wang, P. L., Ohura, K., Takashima, S., Kagami, H., Hirose, Y., Kaku, T., &

Sakaguchi,   K.   (2003).  Solcoseryl,   a   tissue   respiration   stimulating   agent,   significantly

enhances the effect of capacitively coupled electric field on the promotion of bone formation

around   dental   implants. Clinical   oral   implants   research, 14(3),   294–302.